Novo Integrated Sciences (NVOS) S-1/A7 Oct 22IPO registration (amended)Financial data

Company Profile

Cover

Cover	9 Months Ended
Cover	May 31, 2022
Entity Addresses [Line Items]
Document Type	S-1/A
Amendment Flag	true
Amendment Description	Pre-Effective Amendment No. 2
Entity Registrant Name	NOVO INTEGRATED SCIENCES, INC.
Entity Central Index Key	0001138978
Entity Tax Identification Number	59-3691650
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	11120 NE 2nd Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Bellevue
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98004
City Area Code	(206)
Local Phone Number	617-9797
Contact Personnel Name	Robert Mattacchione

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Current Assets:
Cash and cash equivalents	$ 12,677,446	$ 8,293,162	$ 2,067,718
Accounts receivable, net	5,166,239	1,468,429	1,732,432
Inventory, net	645,063	339,385
Other receivables, current portion	1,209,137	814,157	302,664
Prepaid expenses and other current assets	380,800	218,376	191,723
Total current assets	20,078,685	11,133,509	4,294,537
Property and equipment, net	5,931,683	6,070,291	353,660
Intangible assets, net	32,192,858	32,029,499	26,623,448
Right-of-use assets, net	2,222,970	2,543,396	2,810,556
Other receivables, net of current portion		692,738	287,775
Acquisition deposits			383,700
Goodwill	11,366,618	9,488,848	636,942
TOTAL ASSETS	71,792,814	61,958,281	35,390,618
Current Liabilities:
Accounts payable	1,621,719	1,449,784	883,773
Accrued expenses	1,243,792	1,129,309	194,708
Accrued interest (including amounts to related parties)	961,823	366,280	346,264
Government loans and notes payable, current portion	5,260,056	4,485,649	83,292
Convertible notes payable, net of discount of $0	1,875,000
Contingent liability	750,860
Due to related parties	456,528	478,920	528,213
Finance lease liability, current portion	15,982	23,184
Operating lease liability, current portion	544,690	530,797	563,793
Total current liabilities	12,730,450	8,463,923	2,600,043
Debentures, related parties	981,337	982,205	952,058
Notes payable, net of current portion	158,645	5,133,604
Convertible notes payable, net of discount of $5,170,205	10,252,017
Finance lease liability, net of current portion	8,563	16,217
Operating lease liability, net of current portion	1,734,790	2,057,805	2,266,887
Deferred tax liability	1,499,045	1,500,372
TOTAL LIABILITIES	27,364,847	18,154,126	5,818,988
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2022 and August 31, 2021, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 30,659,073 and 26,610,144 shares issued and outstanding at May 31, 2022 and August 31, 2021, respectively	30,659	26,610	23,466
Additional paid-in capital	64,620,878	54,579,396	44,905,454
Common stock to be issued (4,308,591 and 3,622,199 shares at May 31, 2022 and August 31, 2021)	10,096,332	9,236,607
Other comprehensive income	1,015,993	991,077	1,199,696
Accumulated deficit	(31,391,082)	(20,969,274)	(16,507,127)
Total Novo Integrated Sciences, Inc. stockholders’ equity	44,372,780	43,864,416	29,621,489
Noncontrolling interest	55,187	(60,261)	(49,859)
Total stockholders’ equity	44,427,967	43,804,155	29,571,630
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 71,792,814	61,958,281	35,390,618
Previously Reported [Member]
Current Assets:
Cash and cash equivalents		8,293,162
Accounts receivable, net		1,468,429
Inventory, net		339,385
Other receivables, current portion		814,157
Prepaid expenses and other current assets		218,376
Total current assets		11,133,509
Property and equipment, net		6,070,291
Intangible assets, net		32,436,468
Right-of-use assets, net		2,543,396
Other receivables, net of current portion		692,738
Acquisition deposits
Goodwill		9,081,879	$ 636,942
TOTAL ASSETS		61,958,281
Current Liabilities:
Accounts payable		1,449,784
Accrued expenses		1,129,309
Accrued interest (including amounts to related parties)		366,280
Government loans and notes payable, current portion		4,485,649
Due to related parties		478,920
Finance lease liability, current portion		23,184
Operating lease liability, current portion		530,797
Total current liabilities		8,463,923
Debentures, related parties		982,205
Notes payable, net of current portion		5,133,604
Finance lease liability, net of current portion		16,217
Operating lease liability, net of current portion		2,057,805
Deferred tax liability		1,500,372
TOTAL LIABILITIES		18,154,126
Commitments and contingencies
Novo Integrated Sciences, Inc.
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2022 and August 31, 2021, respectively
Common stock; $0.001 par value; 499,000,000 shares authorized; 30,659,073 and 26,610,144 shares issued and outstanding at May 31, 2022 and August 31, 2021, respectively		26,610
Additional paid-in capital		54,579,396
Common stock to be issued (4,308,591 and 3,622,199 shares at May 31, 2022 and August 31, 2021)		9,236,607
Other comprehensive income		991,077
Accumulated deficit		(20,969,274)
Total Novo Integrated Sciences, Inc. stockholders’ equity		43,864,416
Noncontrolling interest		(60,261)
Total stockholders’ equity		43,804,155
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY		$ 61,958,281

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Statement of Financial Position [Abstract]
Convertible preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Convertible preferred stock, shares authorized	1,000,000	1,000,000	1,000,000
Convertible preferred stock, shares issued	0	0	0
Convertible preferred stock, shares outstanding	0	0	0
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	499,000,000	499,000,000	499,000,000
Common stock, shares issued	30,659,073	26,610,144	23,466,236
Common stock, shares outstanding	30,659,073	26,610,144	23,466,236
Common stock to be issued, shares	4,308,591	3,622,199	3,622,199
Convertible notes payable net of discount current	$ 0
Convertible notes payable net of discount noncurrent	$ 5,170,205

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020
Income Statement [Abstract]
Revenues	$ 13,851,883	$ 2,380,974	$ 19,883,033	$ 6,612,374	$ 9,305,255	$ 7,860,567
Cost of revenues	11,443,001	1,100,516	14,991,331	3,769,020	5,482,257	4,802,195
Gross profit	2,408,882	1,280,458	4,891,702	2,843,354	3,822,998	3,058,372
Operating expenses:
Selling expenses	9,802	2,381	36,340	4,226	7,525	4,921
General and administrative expenses	3,601,826	1,680,049	9,542,443	5,324,768	8,089,641	7,286,305
Write down of assets					99,351	29,744
Total operating expenses	3,611,628	1,682,430	9,578,783	5,328,994	8,196,517	7,320,970
Loss from operations	(1,202,746)	(401,972)	(4,687,081)	(2,485,640)	(4,373,519)	(4,262,598)
Non operating income (expense)
Interest income	8,355	8,402	25,233	25,265	45,687	33,627
Interest expense	(513,398)	(21,701)	(1,808,310)	(68,590)	(165,003)	(156,662)
Amortization of debt discount	(2,133,890)		(3,654,752)
Other income (expense)					21,900	(194,055)
Write off of acquisition deposit						(344,521)
Foreign currency transaction gains (losses)	97,654		(303,714)
Total other income (expense)	(2,541,279)	(13,299)	(5,741,543)	(43,325)	(97,416)	(661,611)
Loss before income taxes	(3,744,025)	(415,271)	(10,428,624)	(2,528,965)	(4,470,935)	(4,924,209)
Income tax expense
Net loss	(3,744,025)	(415,271)	(10,428,624)	(2,528,965)	(4,470,935)	(4,924,209)
Net income (loss) attributed to noncontrolling interest	66,029	(4,084)	(6,816)	(6,438)	(8,788)	(9,055)
Net loss attributed to Novo Integrated Sciences, Inc.	(3,810,054)	(411,187)	(10,421,808)	(2,522,527)	(4,462,147)	(4,915,154)
Comprehensive loss:
Net loss	(3,744,025)	(415,271)	(10,428,624)	(2,528,965)	(4,470,935)	(4,924,209)
Foreign currency translation gain	13,711	123,521	24,916	176,349	(208,619)	60,777
Comprehensive loss:	$ (3,730,314)	$ (291,750)	$ (10,403,708)	$ (2,352,616)	$ (4,679,554)	$ (4,863,432)
Weighted average common shares outstanding - basic and diluted	29,817,999	25,298,866	28,498,414	24,192,998	24,774,454	23,034,081
Net loss per common share - basic and diluted	$ (0.13)	$ (0.02)	$ (0.37)	$ (0.10)	$ (0.18)	$ (0.21)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Common Stock to be Issued [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Novo Stockholders Equity [Member]	Noncontrolling Interest [Member]	Total
Beginning balance, value at Aug. 31, 2019	$ 22,369	$ 36,014,525		$ 1,138,919	$ (11,591,973)	$ 25,583,840	$ (39,632)	$ 25,544,208
Beginning balance, shares at Aug. 31, 2019	22,369,150
Common stock issued for cash, net of offering costs	$ 35	113,364				113,399		113,399
Common stock issued for cash, net of offering costs, shares	35,437
Common stock issued for licensing agreement	$ 800	5,247,200				5,248,000		5,248,000
Common stock issued for licensing agreement, shares	800,000
Common stock issued for software license	$ 97	386,134				386,231		386,231
Common stock issued for software license, shares	96,558
Common stock for conversion of convertible notes	$ 15	226,348				226,363		226,363
Common stock for conversion of convertible notes, shares	15,091
Common stock for services	$ 150	589,850				590,000		590,000
Common stock for services, shares	150,000
Fair value of modification of stock option terms		62,822				62,822		62,822
Fair value of stock options		2,265,211				2,265,211		2,265,211
Foreign currency translation gain				60,777		60,777	(1,172)	59,605
Net loss					(4,915,154)	(4,915,154)	(9,055)	(4,924,209)
Ending balance, value at Aug. 31, 2020	$ 23,466	44,905,454		1,199,696	(16,507,127)	29,621,489	(49,859)	29,571,630
Ending balance, shares at Aug. 31, 2020	23,466,236
Common stock issued for cash, net of offering costs	$ 22	91,978				92,000		92,000
Common stock issued for cash, net of offering costs, shares	21,905
Common stock for services	$ 65	247,935				248,000		248,000
Common stock for services, shares	65,000
Foreign currency translation gain				10,596		10,596	(225)	10,371
Net loss					(771,470)	(771,470)	(1,633)	(773,103)
Ending balance, value at Nov. 30, 2020	$ 23,553	45,245,367		1,210,292	(17,278,597)	29,200,615	(51,717)	29,148,898
Ending balance, shares at Nov. 30, 2020	23,553,141
Beginning balance, value at Aug. 31, 2020	$ 23,466	44,905,454		1,199,696	(16,507,127)	29,621,489	(49,859)	29,571,630
Beginning balance, shares at Aug. 31, 2020	23,466,236
Net loss								(2,528,965)
Ending balance, value at May. 31, 2021	$ 26,489	54,297,875		1,376,045	(19,029,654)	36,670,755	(60,630)	36,610,125
Ending balance, shares at May. 31, 2021	26,489,357
Beginning balance, value at Aug. 31, 2020	$ 23,466	44,905,454		1,199,696	(16,507,127)	29,621,489	(49,859)	29,571,630
Beginning balance, shares at Aug. 31, 2020	23,466,236
Common stock issued for cash, net of offering costs	$ 2,410	7,325,170				7,327,580		7,327,580
Common stock issued for cash, net of offering costs, shares	2,409,955
Common stock for services	$ 295	874,878				875,173		875,173
Common stock for services, shares	295,700
Fair value of stock options		155,496				155,496		155,496
Foreign currency translation gain				(208,619)		(208,619)	(1,614)	(210,233)
Net loss					(4,462,147)	(4,462,147)	(8,788)	(4,470,935)
Common stock issued for acquisition	$ 190	430,647				430,837		430,837
Common stock issued for acquisition, shares	189,796
Common stock to be issued for purchase of Mullin assets	$ 240	875,760				876,000		876,000
Common stock issued for intellectual property, shares	240,000
Common stock to be issued for purchase of Acenzia, Inc.			9,236,607			9,236,607		9,236,607
Exercise of stock options	$ 8	11,992				12,000		12,000
Exercise of stock options, shares	7,500
Rounding due to stock split	$ 1	(1)
Rounding due to stock split, shares	957
Ending balance, value at Aug. 31, 2021	$ 26,610	54,579,396	9,236,607	991,077	(20,969,274)	43,864,416	(60,261)	43,804,155
Ending balance, shares at Aug. 31, 2021	26,610,144
Beginning balance, value at Nov. 30, 2020	$ 23,553	45,245,367		1,210,292	(17,278,597)	29,200,615	(51,717)	29,148,898
Beginning balance, shares at Nov. 30, 2020	23,553,141
Foreign currency translation gain				42,232		42,232	(965)	41,267
Net loss					(1,339,870)	(1,339,870)	(721)	(1,340,591)
Exercise of stock options	$ 8	11,992				12,000		12,000
Exercise of stock options, shares	7,500
Rounding due to stock split	$ 1	(1)
Rounding due to stock split, shares	957
Common stock issued for intellectual property	$ 240	875,760				876,000		876,000
Common stock issued for intellectual property, shares	240,000
Common stock to be issued for services rendered			375,000			375,000		375,000
Fair value of vested stock options		22,215				22,215		22,215
Ending balance, value at Feb. 28, 2021	$ 23,802	46,155,333	375,000	1,252,524	(18,618,467)	29,188,192	(53,403)	29,134,789
Ending balance, shares at Feb. 28, 2021	23,801,598
Common stock issued for cash, net of offering costs	$ 2,388	7,233,192				7,235,580		7,235,580
Common stock issued for cash, net of offering costs, shares	2,388,050
Common stock for services	$ 100	374,900	(375,000)
Common stock for services, shares	100,000
Foreign currency translation gain				123,521		123,521	(3,143)	120,378
Net loss					(411,187)	(411,187)	(4,084)	(415,271)
Common stock issued for acquisition	$ 190	430,647				430,837		430,837
Common stock issued for acquisition, shares	189,796
Common stock issued for services rendered	$ 9	37,163				37,172		37,172
Common stock to be issued for services rendered, shares	9,913
Fair value of vested stock options		66,640				66,640		66,640
Ending balance, value at May. 31, 2021	$ 26,489	54,297,875		1,376,045	(19,029,654)	36,670,755	(60,630)	36,610,125
Ending balance, shares at May. 31, 2021	26,489,357
Beginning balance, value at Aug. 31, 2021	$ 26,610	54,579,396	9,236,607	991,077	(20,969,274)	43,864,416	(60,261)	43,804,155
Beginning balance, shares at Aug. 31, 2021	26,610,144
Common stock for services	$ 35	64,715				64,750		64,750
Common stock for services, shares	35,000
Fair value of stock options		154,135				154,135		154,135
Foreign currency translation gain				(103,533)		(103,533)	(855)	(104,388)
Net loss					(1,806,587)	(1,806,587)	(9,808)	(1,816,395)
Common stock to be issued for purchase of Mullin assets			188,925			188,925		188,925
Common stock issued as collateral and held in escrow	$ 2,000	(2,000)
Common stock issued as collateral and held in escrow, shares	2,000,000
Common stock to be issued for purchase of Terragenx			983,925			983,925	97,311	1,081,236
Value of warrants issued with convertible notes		295,824				295,824		295,824
Ending balance, value at Nov. 30, 2021	$ 28,645	55,092,070	10,409,457	887,544	(22,775,861)	43,641,855	26,387	43,668,242
Ending balance, shares at Nov. 30, 2021	28,645,144
Beginning balance, value at Aug. 31, 2021	$ 26,610	54,579,396	9,236,607	991,077	(20,969,274)	43,864,416	(60,261)	43,804,155
Beginning balance, shares at Aug. 31, 2021	26,610,144
Net loss								(10,428,624)
Ending balance, value at May. 31, 2022	$ 30,659	64,620,878	10,096,332	1,015,993	(31,391,082)	44,372,780	55,187	44,427,967
Ending balance, shares at May. 31, 2022	30,659,073
Beginning balance, value at Nov. 30, 2021	$ 28,645	55,092,070	10,409,457	887,544	(22,775,861)	43,641,855	26,387	43,668,242
Beginning balance, shares at Nov. 30, 2021	28,645,144
Common stock for services	$ 240	297,760				298,000		298,000
Common stock for services, shares	240,000
Fair value of stock options		44,427				44,427		44,427
Foreign currency translation gain				114,738		114,738	355	115,093
Net loss					(4,805,167)	(4,805,167)	(63,037)	(4,868,204)
Value of warrants issued with convertible notes		5,257,466				5,257,466		5,257,466
Ending balance, value at Feb. 28, 2022	$ 28,885	60,691,723	10,409,457	1,002,282	(27,581,028)	44,551,319	(36,295)	44,515,024
Ending balance, shares at Feb. 28, 2022	28,885,144
Common stock issued for cash, net of offering costs	$ 225	573,525	(573,750)
Common stock issued for cash, net of offering costs, shares	225,000
Common stock for conversion of convertible notes	$ 624	1,247,225				1,247,849		1,247,849
Common stock for conversion of convertible notes, shares	623,929
Common stock for services	$ 125	313,875				314,000		314,000
Common stock for services, shares	125,000
Fair value of stock options		91,330				91,330		91,330
Foreign currency translation gain				13,711		13,711	51	13,762
Net loss					(3,810,054)	(3,810,054)	66,029	(3,744,025)
Common stock issued for acquisition	$ 800	1,703,200				1,704,000		1,704,000
Common stock issued for acquisition, shares	800,000
Common stock to be issued for acquisitions			260,625			260,625	25,402	286,027
Ending balance, value at May. 31, 2022	$ 30,659	$ 64,620,878	$ 10,096,332	$ 1,015,993	$ (31,391,082)	$ 44,372,780	$ 55,187	$ 44,427,967
Ending balance, shares at May. 31, 2022	30,659,073

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended		12 Months Ended
Condensed Consolidated Statements of Cash Flows - USD ($)	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,428,624)	$ (2,528,965)	$ (4,470,935)	$ (4,924,209)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,349,434	1,118,925	1,724,122	1,445,076
Fair value of vested stock options	289,892	88,855	155,496	2,265,211
Expense associated with modified stock option terms				62,822
Common stock issued for services	676,750	660,172	875,173	590,000
Operating lease expense	418,188	467,864	642,991	541,530
Amortization of debt discount	3,654,752
Gain on forgiveness of debt			(21,900)
Write down of assets			99,351	29,744
Loss on settlement of other receivable				74,360
Write off of acquisition deposit				344,521
Foreign currency transaction losses	303,714
Changes in operating assets and liabilities:
Accounts receivable	(3,650,069)	543,213	1,103,800	(229,015)
Inventory	(263,539)		(147,814)
Prepaid expenses and other current assets	(150,632)	(143,590)	(43,194)	61,218
Accounts payable	117,056	(97,659)	(45,228)	(275,895)
Accrued expenses	(68,871)	64,513	(287,034)	(15,591)
Accrued interest	598,904	7,455	9,015	114,815
Operating lease liability	(406,862)	(460,063)	(618,645)	(526,281)
Net cash used in operating activities	(6,559,907)	(279,280)	(1,024,802)	(441,694)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(190,973)	(201,369)	(255,949)	(12,110)
Cash acquired from (paid for) acquisition	57,489	(10,000)
Cash paid for acquisition			(10,000)
Cash acquired with acquisition			3,738,171
Payment on other receivable	296,138
Amounts loaned for other receivables		(470,040)	(473,100)
Payment for acquisition deposit				(636,985)
Return of acquisition deposit				636,985
Collection of other receivable				669,240
Net cash provided by (used in) investing activities	162,654	(681,409)	2,999,122	657,130
CASH FLOWS FROM FINANCING ACTIVITIES:
Repayments to related parties	(21,932)	(177,534)	(246,327)	(198,778)
Repayments of debenture, related party				(267,696)
Repayments of notes payable	(4,430,794)		(2,767,519)
Repayments of finance leases	(14,797)		(8,872)
Proceeds from government loans and note payable				81,388
Proceeds from the sale of common stock, net of offering costs		7,327,580	7,327,580	113,399
Proceeds from exercise of stock options		12,000	12,000
Proceeds from issuance of convertible notes, net	15,270,000
Net cash provided by financing activities	10,802,477	7,162,046	4,316,862	(271,687)
Effect of exchange rate changes on cash and cash equivalents	(20,940)	97,970	(65,738)	40,303
NET INCREASE IN CASH AND CASH EQUIVALENTS	4,384,284	6,299,327	6,225,444	(15,948)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	8,293,162	2,067,718	2,067,718	2,083,666
CASH AND CASH EQUIVALENTS, END OF PERIOD	12,677,446	8,367,045	8,293,162	2,067,718
CASH PAID FOR:
Interest	1,294,912	33,183	144,987	95,219
Income taxes
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:
Common stock to be issued for intangible assets	188,925	876,000	876,000	5,634,231
Common stock issued for debt				226,363
Common stock to be issued for acquisitions	1,244,550		$ 430,837
Conversion of convertible notes payable and accrued interest to common stock	1,247,849
Common stock issued for acquisition	$ 1,704,000	$ 430,837

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended	12 Months Ended
Organization and Basis of Presentation	May 31, 2022	Aug. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated” or the “Company”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries. The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. Innovation through science, combined with the integration of sophisticated, secure technology, assures Novo Integrated of continued cutting edge advancement in patient first platforms. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited, a wholly owned subsidiary of the Company (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”) and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 16,779,741 85 On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $ 6,904 Reverse Stock Split On February 1, 2021, the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. Impact of COVID-19 In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. On March 17, 2020, as a result of COVID-19 pandemic having been reported throughout both Canada and the United States, certain national, provincial, state and local governmental authorities issued proclamations and/or directives aimed at minimizing the spread of COVID-19. Accordingly, on March 17, 2020, the Company closed all corporate clinics for all in-clinic non-essential services to protect the health and safety of its employees, partners, and patients. Commencing in May 2020, the Company was able to begin providing some services, and was fully operational again in June 2020. As of May 31, 2022, all corporate clinics were open and operational, with staffing shortages in some facilities due to ongoing COVID-19 residual impact, while following all mandated guidelines and protocols from Health Canada, the Ontario Ministry of Health, and the respective disciplines’ regulatory Colleges to ensure a safe treatment environment for our staff and clients, and our eldercare operations are fully operational. In addition, Acenzia Inc. (“Acenzia”), Terragenx Inc. (“Terragenx”), PRO-DIP, LLC (“PRO-DIP”), and Clinical Consultants International LLC (“CCI”), each of which is a wholly owned subsidiary of Novo Integrated, are open and fully operational, with staffing shortages due to ongoing COVID-19 residual impact, while following all local, state, provincial, and national guidelines and protocols related to minimizing the spread of the COVID-19 pandemic. Canadian federal and provincial COVID-19 governmental proclamations and directives, including interprovincial travel restrictions, have presented unprecedented challenges to launching our Harvest Gold Farms and Kainai Cooperative joint ventures during the period ended May 31, 2022. The Company intends to commence pilot projects for each joint venture in the period ended August 31, 2022. These joint ventures relate to the development, management, and arrangement of medicinal farming projects involving industrial hemp for medicinal Cannabidiol (CBD) applications. While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including, but not limited to, (i) the duration of the COVID-19 outbreak and additional variants that may be identified, (ii) new information which may emerge concerning the severity of the COVID-19 pandemic, and (iii) any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic, and reduced operations. For more on the financial impact of COVID-19 on the Company, see “—Liquidity and Capital Resources—Financial Impact of COVID-19” of this quarterly report on Form 10-Q. Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations. The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended August 31, 2021, that the Company filed on December 14, 2021. The results of operations for the nine months ended May 31, 2022 are not necessarily indicative of the results for the fiscal year ending August 31, 2022. The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”); however, the accompanying unaudited condensed consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”). Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used May 31, 2022 May 31, 2021 August 31, 2021 Period end: CAD to USD exchange rate $ 0.7910 $ 0.8284 $ 0.7917 Average period: CAD to USD exchange rate $ 0.7897 $ 0.7834 $ 0.7885	Note 1 - Organization and Basis of Presentation Organization and Line of Business Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000 The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, unique personalized product offerings, and rehabilitative science. For the period ended August 31, 2021, the Company’s revenue was generated primarily through its wholly owned Canadian subsidiary, Novo Healthnet Limited (“NHL”), which provides our services and products through both clinic and eldercare related operations. We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered both now and in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution. The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers: ● First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities. ● Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home. ● Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions. Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting edge advancement in patient first platforms. On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) NHL, (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”) and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated’s common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 16,779,741 85% On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, Novo Integrated Sciences, Inc., were $ 6,904 On November 3, 2017, Novomerica Health Group, Inc. (“Novomerica”) was incorporated, under the laws of the state of Nevada, as a wholly owned subsidiary of the Company for the purpose of expanding the Company’s operations into the United States. On January 7, 2019, 2478659 Ontario Ltd. (“247”) and Kainai Cooperative (“Kainai”) entered into a Joint Venture Agreement (the “Joint Venture Agreement”) for the purpose of developing, managing and arranging for financing of greenhouse and farming projects involving hemp and cannabis cash crops on Kainai related lands, and developing additional infrastructure projects creating jobs and food supply to local communities. On January 8, 2019, we and 247 entered into an Agreement of Transfer and Assignment, pursuant to which 247 agreed to sell, assign and transfer to the Company all rights, contracts, contacts and any and all other assets related in any way to the Joint Venture Agreement. Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to 80% to the Company and 20% to Kainai. 50 years 1,200,000 21,600,000 On February 26, 2019, the Company entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX Inc. (“Cloud DX”) pursuant to which Cloud DX agreed to sell, and NHL agreed to purchase, a fully paid up, perpetual license, with 5-year conditional exclusivity, for the Cloud DX Bundled Pulsewave PAD-1A USB Blood Pressure Device, up-to-date product releases and Licensed Software Products (the “Licensed Software”) to include the: ● Cloud DX Connected Health web portal for clinical users, ● Cloud DX Connected Health mobile app, ● Cloud DX Connected Health Windows app, and ● Cloud DX Connected Health MacOS app. On July 22, 2019, the Company, through NHL, acquired substantially all the assets of Societe Professionnelle de Physiotherapie M Dignard, doing business as Action Plus Physiotherapy Rockland, to expand our corporate owned clinic footprint in the province of Ontario Canada. On September 24, 2019, Novomerica, a wholly owned U.S. based subsidiary of the Company, entered into a Master Facility License Agreement with Fitness International, LLC and Fitness & Sports Clubs, LLC (together with Fitness International, LLC, “LA Fitness U.S.”). On February 24, 2020, this Master Facility License Agreement (the “LA Fitness U.S. Agreement”) was amended pursuant to the terms of that certain First Amendment to the LA Fitness U.S. Agreement. On September 24, 2019, NHL entered into a Master Facility License Agreement with LAF Canada Company (“LA Fitness Canada”). On February 24, 2020, this Master Facility License Agreement (the “LA Fitness Canada Agreement”) was amended pursuant to the terms of that certain First Amendment to the LA Fitness Canada Agreement. On December 17, 2019, the Company entered into that certain Intellectual Property Asset Purchase Agreement (the “APA”) by and between the Company and 2731861 Ontario Corp. (the “Seller”), pursuant to which the Company agreed to purchase, and Seller agreed to sell, proprietary designs for an innovative cannabis dosing device, in addition to designs, plans, procedures, and all other material pertaining to the application, construction, operation, and marketing of a cannabis business under the regulations of Health Canada. Pursuant to the terms of the APA, the purchase price of the Intellectual Property is 800,000 On December 19, 2019, the Company entered into that certain Joint Venture Agreement (the “HGF JV Agreement”) between the Company and Harvest Gold Farms Inc. (“HGF”) relating to the development, management and arrangement of medicinal farming projects involving hemp and cannabis cash crops (the “Project”). Pursuant to the terms of the HGF JV Agreement, the parties agreed to work in a joint venture relationship, with the Company providing the development and operation of the Project, including sales, and HGF providing the land, farming expertise, biomass and necessary approvals for the development of the Project. Pursuant to the terms of the HGF JV Agreement, a corporation, namely, Novo Earth Therapeutics Inc. was formed where we have a 70% The initial term of the HGF JV Agreement will, unless sooner terminated by consent of all parties, expire in five years from the effective date of the HGF JV Agreement. The Company and HGF may renew the HGF JV Agreement within two years of the expiration of the initial term upon mutual understanding. Reverse Stock Split On February 1, 2021, the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. Impact of COVID-19 In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. On March 17, 2020, as a result of COVID-19 pandemic having been reported throughout both Canada and the United States, certain national, provincial, state and local governmental authorities issued proclamations and/or directives aimed at minimizing the spread of COVID-19. Accordingly, on March 17, 2020, the Company closed all corporate clinics for all in-clinic non-essential services to protect the health and safety of its employees, partners, and patients. On May 26, 2020, the Ontario Ministry of Health announced updated guidance and directives stating that physiotherapists, chiropractors, and other regulated health professionals, including services and products provided by the Company, can gradually and carefully begin providing all services, including non-essential services, once the clinician and provider are satisfied all necessary precautions and protocols are in place to protect the patients, the clinician and the clinic staff. With all corporate clinics closed due to the COVID-19 pandemic, with the exception of providing certain limited essential and emergency services, the Company had furloughed 48 full-time employees and 35 part-time employees from its pre-closure levels of 81 full-time employees and 53 part-time employees specific to on-site clinic and eldercare operations. Specific to our clinic-based services and products, operating under COVID-19 related authorized governmental proclamations and directives, between March 17 through June 1, 2020, the Company provided in-clinic multi-disciplinary primary healthcare services and products solely to patients with emergency and essential need while also providing certain virtual based services related to physiotherapy. Specific to our eldercare based services and products, operating under COVID-19 related authorized governmental proclamations and directives which included certain eldercare related services being deemed essential, NHL was able to quickly expand its existing eldercare related physiotherapy service “virtual-care” platform, which pre-pandemic was primarily focused on providing “virtual-care” services to both smaller and remote eldercare homes to ensure access to service providers, when needed; and continuity of care to eldercare patients without service providers in their area. Given NHL had established “virtual care” procedures and forms, complete with video consent and assessment forms already vetted and approved by the Ontario College of Physiotherapists, NHL was well-positioned to expand the delivery of certain of its eldercare related contracted services, via “virtual-care” technology, ensuring continuity of service for our long-term care and retirement home clients. On June 2, 2020, the Company commenced opening its corporate clinics and providing non-essential services. As of the year ended August 31, 2021, all corporate clinics are open and operational while following all mandated guidelines and protocols from Health Canada, the Ontario Ministry of Health, and the respective disciplines’ regulatory Colleges to ensure a safe treatment environment for our staff and clients. Canadian federal and provincial COVID-19 governmental proclamations and directives, including interprovincial travel restrictions, have presented unprecedented challenges to launching our Harvest Gold Farms and Kainai Cooperative joint ventures during the fiscal year ended August 31, 2021. Accordingly, the Company has decided to delay commencing the projects until the 2022 grow season. These joint ventures relate to the development, management, and arrangement of medicinal farming projects involving industrial hemp for medicinal Cannabidiol (CBD) applications. As of August 31, 2021, the Company has 73 full-time employees and 56 part-time employees specific to on-site clinic and eldercare operations. Specific to PRO-DIP, LLC (“PRO-DIP”) and Acenzia, Inc. (“Acenzia”), both companies are open and fully operational while following all local, state, provincial, and national guidelines and protocols related to minimizing the spread of the COVID-19 pandemic. While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations. Basis of Presentation The accompanying consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”); however, the accompanying consolidated financial statements were translated and presented in United States Dollars (“$” or “USD”). Foreign Currency Translation The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction Comprehensive Income Schedule of Foreign Currency Translation, Exchange Rate Used August 31, August 31, 2021 2020 Period end: CAD to USD exchange rate $ 0.7917 $ 0.7674 Average period: CAD to USD exchange rate $ 0.7885 $ 0.7435

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies	May 31, 2022	Aug. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia, Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, a 91 50.1 80 70 An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of other comprehensive income (“OCI”) are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive loss is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends, and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2022, and August 31, 2021, the allowance for uncollectible accounts receivable was $ 705,384 1,097,628 Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of May 31, 2022 and August 31, 2021, the Company’s allowance for slow moving or obsolete inventory was $ 1,065,777 1,066,721 Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5 Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Software license 7 Intellectual property 7 Customer relationships 5 Brand names 7 The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at May 31, 2022, the Company believes there was no impairment of its intangible assets. Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. during the fiscal year ended August 31, 2017, Executive Fitness Leaders during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland during the fiscal year ended August 31, 2019, Acenzia Inc. during fiscal year ended August 31, 2021 and 12858461 Canada Corp., Fairway Physiotherapy and Sports Injury Clinic, and Clinical Consultants International LLC during fiscal year ending August 31, 2022. Based on its review at May 31, 2022, the Company believes there was no impairment of its goodwill. As of August 31, 2021, the Company performed the required impairment reviews and determined that an impairment charge of $ 99,593 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and equivalents, accounts receivable, other receivables, accounts payable and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, current portion of other receivables, and current liabilities, including accounts payable, current portion of notes payable, due to related parties, current portion of convertible notes payable and current portion of operating and finance lease liabilities, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of May 31, 2022 and August 31, 2021, respectively, the Company did not identify any financial assets and liabilities required to be presented on the balance sheet at fair value. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying condensed consolidated balance sheets. Sales returns and allowances were insignificant for the periods ended May 31, 2022 and 2021. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 10,624,849 1,849,600 8,270,812 4,308,591 Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $ 1,015,993 991,077 Statement of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the condensed consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the condensed consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting Concentrations At May 31, 2022, one customer accounted for approximately 40 70 50 Reclassifications Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity. Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes In May, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. In August 2020, the FASB issued guidance that simplifies the accounting for debt with conversion options, revises the criteria for applying the derivative scope exception for contracts in an entity’s own equity, and improves the consistency for the calculation of earnings per share. The guidance is effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2021. In March 2020, the FASB issued guidance providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020 and can be applied through December 21, 2022, has not impacted our condensed consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2022. Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.	Note 2 – Summary of Significant Accounting Policies Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Novomerica Health Group, Inc., Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC, Acenzia, Inc., an 80% 70% An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity. Income or loss and each component of OCI are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive income is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation. Noncontrolling Interest The Company follows FASB ASC Topic 810, Consolidation, The net income (loss) attributed to the NCI is separately designated in the accompanying consolidated statements of operations and comprehensive loss. Cash Equivalents For the purpose of the consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. Accounts Receivable Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of August 31, 2021 and 2020, the allowance for uncollectible accounts receivable was $ 1,097,628 518,031 Inventory Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenue in the accompanying consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of August 31, 2021, the Company’s allowance for slow moving or obsolete inventory was $ 1,066,721 Other Receivables Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the years ended August 31, 2021 and 2020, the Company wrote off $ 0 29,744 Property and Equipment Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows: Schedule of Estimated Useful Lives of Assets Building 30 years Leasehold improvements 5 years Clinical equipment 5 years Computer equipment 3 years Office equipment 5 years Furniture and fixtures 5 years Leases The Company applies the provisions of ASC Topic 842, Leases Long-Lived Assets The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment Intangible Assets The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 years Software license 7 years Intellectual property 7 years Customer relationships 5 years Brand names 7 years Workforce 5 years The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at August 31, 2021 and 2020, the Company believes there was no impairment of its intangible assets. Right-of-use Assets The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which 12 months Goodwill Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. during the fiscal year ended August 31, 2017, Executive Fitness Leaders during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland during the fiscal year ended August 31, 2019 and Acenzia, Inc. during fiscal year ended August 31, 2021. Based on its review at August 31, 2020, the Company believes there was no impairment of its goodwill. As of August 31, 2021, the Company performed the required impairment reviews and determined that an impairment charge of $ 99,593 Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia Total Balance, August 31, 2019 $ 187,675 $ 217,703 $ 217,703 $ - $ 623,081 Foreign currency translation adjustment 4,175 4,843 4,843 - 13,861 Balance, August 31, 2020 191,850 222,546 222,546 - 636,942 Goodwill acquired with purchase of business - - - 8,726,949 8,726,949 Impairment of goodwill - (99,593 ) - - (99,593 ) Foreign currency translation adjustment 6,075 6,886 7,047 (202,427 ) (182,419 ) Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,524,522 $ 9,081,879 Acquisition Deposits The Company has signed letters of understanding with a potential acquisition candidate which includes refundable acquisition deposits totaling $ 383,700 10 September 1, 2022 Fair Value of Financial Instruments For certain of the Company’s financial instruments, including cash and equivalents, accounts receivable, other receivables, accounts payable, government loans and notes payable, and due to related parties, the carrying amounts approximate their fair values due to their short-term maturities. FASB ASC Topic 820, Fair Value Measurements and Disclosures Financial Instruments ● Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement. The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity Derivatives and Hedging For certain financial instruments, the carrying amounts reported in the balance sheets for cash, accounts receivable, current portion of other receivables, and current liabilities, including accounts payable, short-term notes payable, due to related parties and finance lease obligations, each qualify as a financial instrument, and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The carrying value of notes payable approximates their fair values due to current market rate on such debt. As of August 31, 2021 and 2020, respectively, the Company did not identify any financial assets and liabilities required to be presented on the balance sheet at fair value, except for cash and cash equivalents which are carried at fair value using Level 1 inputs. Revenue Recognition The Company’s revenue recognition reflects the updated accounting policies as per the requirements of ASU No. 2014-09, Revenue from Contracts with Customers Revenue from providing healthcare and healthcare related services and product sales are recognized under Topic 606 ● executed contracts with the Company’s customers that it believes are legally enforceable; ● identification of performance obligations in the respective contract; ● determination of the transaction price for each performance obligation in the respective contract; ● allocation the transaction price to each performance obligation; and ● recognition of revenue only when the Company satisfies each performance obligation. These five elements, as applied to the Company’s revenue category, are summarized below: ● Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes. ● Product sales – revenue is recorded at the point of time of delivery Payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as unearned revenue. Unearned revenue is included with accrued expenses in the accompanying consolidated balance sheets. Sales returns and allowances were insignificant for the years ended August 31, 2021 and 2020. The Company does not provide unconditional right of return, price protection or any other concessions to its customers. Income Taxes The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented. Stock-Based Compensation The Company records stock-based compensation in accordance with FASB ASC Topic 718, Compensation – Stock Compensation Basic and Diluted Earnings Per Share Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share 4,237,650 1,784,500 Foreign Currency Transactions and Comprehensive Income U.S. GAAP generally requires recognized revenue, expenses, gains and losses be included in net income. Certain statements, however, require entities to report specific changes in assets and liabilities, such as gain or loss on foreign currency translation, as a separate component of the equity section of the balance sheet. Such items, along with net income, are components of comprehensive income. The functional currency of the Company’s Canadian subsidiaries is the CAD. Translation gains of $ 991,077 and $ 1,199,696 at August 31, 2021 and 2020, respectively, are classified as an item of other comprehensive income in the stockholders’ equity section of the consolidated balance sheet. Statement of Cash Flows Cash flows from the Company’s operations are calculated based upon the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance sheets. Segment Reporting ASC Topic 280, Segment Reporting Recent Accounting Pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes Income Taxes In May, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40):Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. In August 2020, the FASB issued guidance that simplifies the accounting for debt with conversion options, revises the criteria for applying the derivative scope exception for contracts in an entity’s own equity, and improves the consistency for the calculation of earnings per share. The guidance is effective for annual reporting periods and interim periods within those annual reporting periods beginning after December 15, 2021. In March 2020, the FASB issued guidance providing optional expedients and exceptions to account for the effects of reference rate reform to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued. The optional guidance, which became effective on March 12, 2020 and can be applied through December 21, 2022, has not impacted our consolidated financial statements. The Company has various contracts that reference LIBOR and is assessing how this standard may be applied to specific contract modifications through December 31, 2022. Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Related Party Transactions

Related Party Transactions	9 Months Ended	12 Months Ended
Related Party Transactions	May 31, 2022	Aug. 31, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At May 31, 2022 and August 31, 2021, the amount due to related parties was $ 456,528 478,920 384,723 22,763 6 49,042 13.75 407,052 22,783 6 49,085 13.75	Note 3 – Related Party Transactions Due to related parties Amounts loaned to the Company by stockholders and officers of the Company are payable upon demand and unsecured. At August 31, 2021 and 2020, the amount due to related parties was $ 478,920 528,213 407,052 22,783 49,085 13.75% 458,550 22,084 47,579 The Company leased office space from a related party on a month-to-month basis with monthly lease payments of $ 1,487 On July 21, 2020, a related party converted $ 226,363 15,091 15.00 On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 . The remaining principal balance of debentures due to related parties at August 31, 2021 and 2020 was $ 982,205 and $ 952,058 , respectively.

Inventory

Inventory	9 Months Ended	12 Months Ended
Inventory	May 31, 2022	Aug. 31, 2021
Inventory Disclosure [Abstract]
Inventory	Note 5 – Inventory Inventory at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Inventory May 31, August 31, 2022 2021 Raw materials $ 1,162,067 $ 1,017,566 Work in process 144,500 144,628 Finished Goods 404,273 243,912 Inventory Gross 1,710,840 1,406,106 Allowance for slow moving and obsolete inventory (1,065,777 ) (1,066,721 ) Inventory, net $ 645,063 $ 339,385	Note 4 – Inventory Inventory at August 31, 2021 and 2020 consisted of the following: Schedule of Inventory 2021 2020 Raw materials $ 1,017,566 $ - Work in process 144,628 - Finished Goods 243,912 - Inventory, Gross 1,406,106 - Allowance for slow moving and obsolete inventory (1,066,721 ) - Inventory, net $ 339,385 $ -

Accounts Receivables, net

Accounts Receivables, net	9 Months Ended	12 Months Ended
Accounts Receivables, net	May 31, 2022	Aug. 31, 2021
Receivables [Abstract]
Accounts Receivables, net	Note 4 – Accounts Receivables, net Accounts receivables, net at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Accounts Receivables, Net May 31, August 31, 2022 2021 Trade receivables $ 5,739,193 $ 2,411,499 Amounts earned but not billed 132,430 154,558 Accounts receivable gross 5,871,623 2,566,057 Allowance for doubtful accounts (705,384 ) (1,097,628 ) Accounts receivable, net $ 5,166,239 $ 1,468,429	Note 5 – Accounts Receivables, net Accounts receivables, net at August 31, 2021 and 2020 consisted of the following: Schedule of Accounts Receivables, Net 2021 2020 Trade receivables $ 2,411,499 $ 1,948,520 Amounts earned but not billed 154,558 301,943 Accounts receivable, Gross 2,566,057 2,250,463 Allowance for doubtful accounts (1,097,628 ) (518,031 ) Accounts receivable, net $ 1,468,429 $ 1,732,432

Other Receivables

Other Receivables	9 Months Ended	12 Months Ended
Other Receivables	May 31, 2022	Aug. 31, 2021
Receivables [Abstract]
Other Receivables	Note 6 – Other Receivables Other receivables at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Other Receivables May 31, August 31, 2022 2021 Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8 March 1, 2019 $ - $ 296,888 Advance to corporation; accrues interest at 12 January 31, 2023 79,100 79,170 Advance to corporation; accrues interest at 10 May 1, 2023 225,924 225,924 Advance to corporation; accrues interest at 12 August 1, 2022 508,613 509,063 Advance to corporation; accrues interest at 10 September 1, 2022 395,500 395,850 Total other receivables 1,209,137 1,506,895 Current portion (1,209,137 ) (814,157 ) Long-term portion $ - $ 692,738	Note 6 – Other Receivables Other receivables at August 31, 2021 and 2020 consisted of the following: Schedule of Other Receivables 2021 2020 296,888 287,775 Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% March 1, 2019 $ 296,888 $ 287,775 Advance to corporation; accrues interest at 12% December 31, 2021 79,170 76,740 Advance to corporation; accrues interest at 10% March 1, 2022 225,924 225,924 Advance to corporation; accrues interest at 12% February 1, 2022 509,063 - Advance to corporation; accrues interest at 10% September 1, 2022 395,850 - Total other receivables 1,506,895 590,439 Current portion (814,157 ) (302,664 ) Long-term portion $ 692,738 $ 287,775 During the year ended August 31, 2020, the Company settled other receivable for less than the amount due and recognized a loss on settlement of $ 74,360 29,744

Property and Equipment

Property and Equipment	9 Months Ended	12 Months Ended
Property and Equipment	May 31, 2022	Aug. 31, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Note 7 – Property and Equipment Property and equipment at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Property and Equipment May 31, August 31, 2022 2021 Land $ 474,600 $ 475,020 Building 3,559,500 3,562,650 Leasehold improvements 861,188 691,318 Clinical equipment 1,973,582 1,875,537 Computer equipment 27,116 24,679 Office equipment 49,842 46,510 Furniture and fixtures 40,983 41,019 Property and equipment gross 6,986,811 6,716,733 Accumulated depreciation (1,055,128 ) (646,442 ) Total $ 5,931,683 $ 6,070,291 Depreciation expense for the nine months ended May 31, 2022 and 2021 was $ 408,589 and $ 57,840 , respectively. Certain property and equipment have been used to secure notes payable (See Note 10).	Note 7 – Property and Equipment Property and equipment at August 31, 2021 and 2020 consisted of the following: Schedule of Property and Equipment 2021 2020 Land $ 475,020 $ - Building 3,562,650 - Leasehold improvements 691,318 465,857 Clinical equipment 1,875,537 301,337 Computer equipment 24,679 23,921 Office equipment 46,510 29,229 Furniture and fixtures 41,019 39,760 6,716,733 860,104 Accumulated depreciation (646,442 ) (506,444 ) Total $ 6,070,291 $ 353,660 Depreciation expense for the years ended August 31, 2021 and 2020 was $ 123,461 75,726 Certain property and equipment has been used to secure notes payable (See Note 10).

Intangible Assets

Intangible Assets	9 Months Ended	12 Months Ended
Intangible Assets	May 31, 2022	Aug. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Note 8 – Intangible Assets Intangible assets at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Intangible Assets May 31, August 31, 2022 2021 Land use rights $ 21,600,000 $ 21,600,000 Software license 1,144,798 1,144,798 Intellectual property 11,495,963 9,388,065 Customer relationships 786,608 787,304 Brand names 2,064,115 2,065,941 37,091,484 34,986,108 Accumulated amortization (4,898,626 ) (2,956,609 ) Total $ 32,192,858 $ 32,029,499 Amortization expense for the nine months ended May 31, 2022 and 2021 was $ 1,940,845 1,061,085 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of Intangible Assets Twelve Months Ending May 31, 2023 $ 2,690,018 2024 2,690,018 2025 2,690,018 2026 2,662,926 2027 2,115,863 Thereafter 19,344,015 Total $ 32,192,858	Note 8 – Intangible Assets Intangible assets at August 31, 2021 and 2020 consisted of the following: Schedule of Intangible Assets 2021 2020 Land use rights $ 21,600,000 $ 21,600,000 Software license 1,144,798 1,144,798 Intellectual property 9,388,065 5,248,000 Customer relationships 787,304 - Brand names 2,065,941 - Assembled workforce 421,003 - 35,407,111 27,992,798 Accumulated amortization (2,970,643 ) (1,369,350 ) Total $ 32,436,468 $ 26,623,448 Amortization expense for the years ended August 31, 2021 and 2020 was $ 1,600,661 1,369,350 Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of Intangible Assets 2022 $ 2,473,490 Years Ending August 31, 2022 $ 2,473,490 2023 2,473,490 2024 2,473,490 2025 2,473,490 2026 2,379,029 Thereafter 20,163,479 Total $ 32,436,468 On December 17, 2019, the Company entered into that certain Intellectual Property Asset Purchase Agreement (the “APA”) by and between the Company and 2731861 Ontario Corp. (the “Seller”), pursuant to which the Company agreed to purchase, and Seller agreed to sell (the “Acquisition”), proprietary designs for an innovative cannabis dosing device, in addition to designs, plans, procedures, and all other material pertaining to the application, construction, operation, and marketing of a cannabis business under the regulations of Health Canada (the “Intellectual Property”). Pursuant to the terms of the APA, the purchase price of the Intellectual Property is 800,000 5,248,000 On February 26, 2019, the Company and NHL entered into a Software License Agreement (the “Cloud DX License”) with Cloud DX Inc. (“Cloud DX”), pursuant to which Cloud DX agreed to sell, and NHL agreed to purchase, a fully paid up, perpetual license, with 5-year conditional exclusivity, for the Cloud DX Bundled Pulsewave PAD-1A USB Blood Pressure Device, up-to-date product releases and Licensed Software Products (the “Licensed Software”). Pursuant to the terms of the Cloud DX License, Cloud DX also agreed to sell, and NHL agreed to purchase, 4,000 fully functional Pulsewave PAD 1A USB blood pressure monitor devices bundled with the perpetual license discussed above (the “Bundled Devices”). The Cloud DX License granted to NHL and its majority-owned subsidiaries, holding companies, divisions and affiliates, other than physiotherapy clinics owned and operated by Closing The Gap Healthcare Inc., the right to use and sub-license the Licensed Software and re-sell the Bundled Devices pursuant to the terms of the Cloud DX License in the physical therapy clinic marketplace in North America in exchange for the purchase price as set forth below: ● Upon the closing, the Company issued 45,835 1,000,000 758,567 ● Cloud DX agreed to invoice CAD$ 250,000 189,642 Schedule of Software Deliverables and Payments Cloud DX deliverable Novo payment (terms: Net 15) Heart Friendly Program launches in Clinic #1 CAD$ 50,000 37,929 Novo-branded Android app delivered as APK file CAD$ 35,000 26,550 Novo-branded Clinical portal website delivered CAD$ 35,000 26,550 Pulsewave PAD-1A devices – 1 st CAD$ 20,000 15,171 Marketing services / materials delivered CAD$ 25,000 18,964 Cloud DX hires dedicated Novo support FTE CAD$ 85,000 64,478 On March 9, 2020, the Company and NHL entered into that certain First Amendment to Cloud DX Perpetual Software License Agreement (the “Cloud DX Amendment”) with Cloud DX, effective March 6, 2020, pursuant to which the parties thereto agreed that the CAD$ 250,000 186,231 46,558 200,000 50,000 Except as set forth in the Cloud DX Amendment, the remaining terms and conditions of the Cloud DX License remain in full force and effect. In connection with the acquisition of PRO-DIP (see Note 15) the Company acquired intellectual property valued at $ 455,752 In connection with the acquisition of Acenzia (See Note 15) the Company acquired the following intangible assets: intellectual property valued at $ 2,875,000 806,000 2,115,000 431,000

Accrued Expenses

Accrued Expenses	9 Months Ended	12 Months Ended
Accrued Expenses	May 31, 2022	Aug. 31, 2021
Payables and Accruals [Abstract]
Accrued Expenses	Note 9 – Accrued Expenses Accrued expenses at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Accrued Expenses May 31, August 31, 2022 2021 Accrued liabilities $ 1,023,005 $ 811,660 Accrued payroll 182,231 279,018 Unearned revenue 38,556 38,631 Accrued expenses $ 1,243,792 $ 1,129,309	Note 9 – Accrued Expenses Accrued expenses at August 31, 2021 and 2020 consisted of the following: Schedule of Accrued Expenses 2021 2020 Accrued liabilities $ 811,660 $ 37,457 Accrued payroll 279,018 117,823 Unearned revenue 38,631 39,428 Accrued expenses $ 1,129,309 $ 194,708

Government Loans and Note Payab

Government Loans and Note Payable and Government Subsidy	9 Months Ended	12 Months Ended
Government Loans and Note Payable and Government Subsidy	May 31, 2022	Aug. 31, 2021
Government Loans And Note Payable And Government Subsidy
Government Loans and Note Payable and Government Subsidy	Note 10 – Government Loans and Notes Payable Government Loans and Note Payable and Government Subsidy Notes payable at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Governmental Loans and Note Payable May 31, August 31, 2022 2021 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 94,920 63,336 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 monthly 190 40,320 40,320 Note payable dated December 3, 2019; accrues interest at 3 June 30, 2022 5,252,749 5,069,858 Note payable dated December 3, 2018; accrues interest at 4.53 annual 4,000 December 31, 2028 30,712 30,739 Note payable dated June 24, 2021; accrues interest at 9 950,000 June 24, 2022 - 4,415,000 Total government loans and notes payable 5,418,701 9,619,253 Less current portion (5,260,056 ) (4,485,649 ) Long-term portion $ 158,645 $ 5,133,604 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 63,280 If the loan amount is paid on or before December 31, 2023, 25 75 60,000 20,000 31,640 Government Subsidy In 2020, the Government of Canada announced the Canada Emergency Wage Subsidy (“CEWS”) for Canadian employers whose businesses were affected by the COVID-19 pandemic. The CEWS provides a subsidy of up to 75 731,000 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable Twelve Months Ending May 31, 2023 $ 5,260,056 2024 99,822 2025 5,343 2026 5,790 2027 6,244 Thereafter 41,446 Total $ 5,418,701	Note 10 – Government Loans and Note Payable and Government Subsidy Governmental loans and note payable at August 31, 2021 and 2020 consisted of the following: Schedule of Governmental Loans and Note Payable 2021 2020 Note payable issued under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The loan has terms of 24 months and accrues interest at 1% $ - $ 21,900 Note payable issued under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The loan has terms of 24 months 1% $ - $ 21,900 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 63,336 61,392 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75% monthly 190 40,320 - Note payable dated December 3, 2019; accrues interest at 3% June 30, 2022 5,069,858 - Note payable dated December 3, 2018; accrues interest at 4.53% annual 4,000 December 2, 2028 30,739 - Note payable dated June 24, 2021; accrues interest at 9% 950,000 June 24, 2022 4,415,000 - Total government loans and notes payable 9,619,253 83,292 Less current portion (4,485,649 ) (83,292 ) Long-term portion $ 5,133,604 $ - (A) The Government of Canada launched the Canada Emergency Business Account loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 63,336 December 31, 2022 If the loan amount is paid on or before December 31, 2022, 25% Government Subsidy In 2020, the Government of Canada announced the Canada Emergency Wage Subsidy (“CEWS”) for Canadian employers whose businesses were affected by the COVID-19 pandemic. The CEWS provides a subsidy of up to 75% of eligible employees’ employment insurable remuneration, subject to certain criteria. Accordingly, the Company applied for the CEWS to the extent it met the requirements to receive the subsidy and during the year ended August 31, 2021, recorded a total of approximately $ 731,000 Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable 2022 $ 4,485,649 Years Ending August 31, 2022 $ 4,485,649 2023 5,074,763 2024 5,346 2025 5,793 2026 6,247 Thereafter 41,455 Total $ 9,619,253

Debentures, Related Parties

Debentures, Related Parties	9 Months Ended	12 Months Ended
Debentures, Related Parties	May 31, 2022	Aug. 31, 2021
Debt Disclosure [Abstract]
Debentures, Related Parties	Note 12 – Debentures, Related Parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 (approximately $ 6,225,163 on September 30, 2013) in connection with the acquisition of certain business assets. The holders of the debentures are current stockholders, officers and/or affiliates of the Company. The debentures are secured by all the assets of the Company, accrue interest at 8 % per annum and were originally due on September 30, 2016 . On December 2, 2017, the debenture holders agreed to extend the due date to September 30, 2019 . On September 27, 2019, the debenture holders agreed to extend the due date to September 30, 2021. On November 2, 2021, the debenture holders agreed to extend the due date to December 1, 2023 On January 31, 2018, the debenture holders converted 75 3,894,809 414,965 1,047,588 The per share price used for the conversion of each debenture was $ 4.11 On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At May 31, 2022 and August 31, 2021, the amount of debentures outstanding was $ 981,337 982,205	Note 11 – Debentures, related parties Debentures, Related Parties On September 30, 2013, the Company issued five debentures totaling CAD$ 6,402,512 6,225,163 8% September 30, 2016 September 30, 2019 September 30, 2021 December 1, 2023 On January 31, 2018, the debenture holders converted 75% 3,894,809 414,965 1,047,588 The per share price used for the conversion of each debenture was $ 4.11 On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $ 267,768 At August 31, 2021 and 2020, the amount of debentures outstanding was $ 982,205 952,058

Leases

Leases	9 Months Ended	12 Months Ended
Leases	May 31, 2022	Aug. 31, 2021
Leases
Leases	Note 13 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of May 31, 2022 and August 31, 2021: Schedule of Lease Related Assets and Liabilities May 31, August 31, 2022 2021 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,222,970 $ 2,543,396 Total lease assets $ 2,222,970 $ 2,543,396 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 544,690 $ 530,797 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,734,790 2,057,805 Total lease liability $ 2,279,480 $ 2,588,602 Future minimum operating lease payments are as follows: Schedule of Lease Obligations Twelve Months Ending May 31, 2023 $ 707,309 2024 491,435 2025 406,221 2026 379,585 2027 378,902 Thereafter 464,438 Total payments 2,827,890 Amount representing interest (548,410 ) Lease obligation, net 2,279,480 Less lease obligation, current portion (544,690 ) Lease obligation, long-term portion $ 1,734,790 During the nine months ended May 31, 2022, the Company entered into new lease obligation of $ 100,711 The lease expense for the nine months ended May 31, 2022 and 2021 was $ 567,772 629,029 556,445 621,228 5.55 8 Finance Leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5 The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at May 31, 2022 and August 31, 2021 is as follows: Schedule of Finance Leases May 31, August 31, 2022 2021 Cost $ 209,457 $ 209,457 Accumulated amortization (178,383 ) (136,491 ) Net book value $ 31,074 $ 72,966 Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending May 31, 2023 $ 16,631 2024 8,092 Total payments 24,723 Amount representing interest (178 ) Lease obligation, net 24,545 Less lease obligation, current portion (15,982 ) Lease obligation, long-term portion $ 8,563	Note 12 – Leases Operating leases The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company discounts lease payments based on an estimate of its incremental borrowing rate. The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2028. The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2021 and 2020: Schedule of Lease Related Assets and Liabilities 2021 2020 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,543,396 $ 2,810,556 Total lease assets $ 2,543,396 $ 2,810,556 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 530,797 $ 563,793 Noncurrent liabilities Operating lease liability Long-term operating lease liability 2,057,805 2,266,887 Total lease liability $ 2,588,602 $ 2,830,680 Lease obligations at August 31, 2021 consisted of the following: Schedule of Lease Obligations Years Ending August 31, 2022 $ 717,772 2023 649,974 2024 444,301 2025 366,620 2026 351,434 Thereafter 728,841 Total payments 3,258,942 Amount representing interest (670,340 ) Lease obligation, net 2,588,602 Less lease obligation, current portion (530,797 ) Lease obligation, long-term portion $ 2,057,805 During the year ended August 31, 2021, the Company entered into new lease obligation of $ 296,317 The lease expense for the years ended August 31, 2021 and 2020 was $ 858,847 788,272 834,502 772,798 At August 31, 2021, the weighted average remaining lease terms were 5.98 8 Finance leases The Company leases certain equipment under lease contracts that are accounted for as finance leases. If the contracts meet the criteria for a finance lease, the related equipment underlying the lease contract is capitalized and amortized over its estimated useful life. If the cost of the equipment is not available, the Company calculates the cost by taking the present value of the lease payments using an implicit borrowing rate of 5%. The net book value of equipment under finance leases included in property and equipment on the accompanying balance sheet at August 31, 2021 is as follows: Schedule of Finance Leases Cost $ 209,457 Accumulated amortization (136,491 ) Net book value $ 72,966 Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Years Ending August 31, 2022 $ 25,153 2023 9,719 2024 5,669 Total payments 40,541 Amount representing interest (1,140 ) Lease obligation, net 39,401 Less lease obligation, current portion (23,184) Lease obligation, long-term portion $ 16,217

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended	12 Months Ended
Stockholders’ Equity	May 31, 2022	Aug. 31, 2021
Equity [Abstract]
Stockholders’ Equity	Note 14 – Stockholders’ Equity Convertible Preferred Stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. At May 31, 2022 and August 31, 2021, there were 30,659,073 26,610,144 During the nine months ended May 31, 2022, the Company issued: ● 35,000 64,750 September 16, 2021 ● 2,000,000 November 17, 2021 1,875,000 0 ● 50,000 65,500 December 20, 2021 ● 25,000 30,000 January 24, 2022 ● 65,000 78,000 January 24, 2022 ● 50,000 60,000 January 24, 2022 ● 50,000 64,500 February 24, 2022 ● 50,000 restricted shares of common stock as consideration for an Independent Contractor Agreement valued at $ 138,000 March 18, 2022 ● 25,000 69,000 March 18, 2022 ● 800,000 restricted shares of common stock as consideration for a Membership Interest Purchase Agreement valued at $ 1,704,000 April 7, 2022 ● 50,000 107,000 May 2, 2022 ● 225,000   restricted shares of common stock issued for NHL Exchangeable Shares under the terms and conditions of a Share Exchange Agreement which closed on June 24, 2021. The fair value was determined based on the market price of the Company’s common stock on the date of closing. The shares were issued on May 11, 2022 ● 623,929   shares of common stock as consideration for payment of an aggregate principal amount of $ 1,244,444 3,405 Stock Options On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorized the issuance of up to 500,000 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 1,000,000 864,900 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 4,500,000 the maximum aggregate number of shares that may be issued under the 2021 Plan is eligible to be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2022. As of May 31, 2022, the 2021 Plan had 4,039,315 The following is a summary of stock options activity: Schedule of Stock Option and Warrant Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 1,849,600 2.29 3.14 $ 218,240 Granted 329,985 1.41 Forfeited - Exercised - Outstanding, May 31, 2022 2,179,585 2.16 2.74 $ 658,069 Exercisable, May 31, 2022 1,968,096 $ 2.25 2.52 $ 505,797 The exercise price for stock options outstanding at May 31, 2022: Schedule of Options and Warrants Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 281,985 $ 1.33 70,496 $ 1.33 997,000 1.60 997,000 1.60 48,000 1.87 48,000 1.87 775,000 3.00 775,000 3.00 72,600 3.80 72,600 3.80 5,000 5.00 5,000 5.00 2,179,585 1,968,096 For options granted during the nine months ended May 31, 2022 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 1.37 1.41 For options granted during the nine months ended May 31, 2021 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 3.76 3.80 The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ 289,892 88,855 273,991 The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the nine months ended May 31, 2022 and 2021: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2022 2021 Risk-free interest rate 0.93 1.89 % 0.42 % Expected life of the options 2.5 2.5 Expected volatility 281 % 268 % Expected dividend yield 0 % 0 % Warrants The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 2,388,050 3.35 5.12 $ - Granted 6,057,214 2.05 Forfeited - Exercised - Outstanding, May 31, 2022 8,445,264 2.42 3.75 $ 291,667 Exercisable, May 31, 2022 8,445,264 $ 2.42 3.75 $ 291,667 The exercise price for warrants outstanding at May 31, 2022: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 5,833,334 $ 2.00 2,611,930 3.35 8,445,264	Note 13 – Stockholders’ Equity Convertible preferred stock The Company has authorized 1,000,000 0.001 0 0 Common Stock The Company has authorized 499,000,000 0.001 the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share 26,610,144 23,466,236 During the fiscal year ended August 31, 2021, the Company issued: ● 21,905 92,000 ● 15,000 55,500 ● 50,000 192,500 ● 240,000 876,000 3.65 ● 957 ● 7,500 12,000 ● 100,000 375,000 ● 9,913 37,172 ● 2,388,050 3.35 764,388 ● 189,796 430,837 2.27 ● 120,787 215,000 During the fiscal year ended August 31, 2020, the Company issued: ● 800,000 5,248,000 6.56 ● 96,558 386,231 4.00 ● 15,091 304,321 226,363 15.00 ● 100,000 340,000 ● 50,000 250,000 ● 35,437 113,399 Common Stock to be Issued In connection with the acquisition of Acenzia (See Note 15), the Company is obligated to issue 3,622,199 Stock Options and Warrants On September 8, 2015, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2015 Incentive Compensation Plan (the “2015 Plan”), which authorizes the issuance of up to 500,000 On January 16, 2018, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2018 Incentive Compensation Plan (the “2018 Plan”). Under the 2018 Plan, 1,000,000 864,900 On February 9, 2021, the Company’s Board of Directors and stockholders holding a majority of the Company’s outstanding common stock approved the Novo Integrated Sciences, Inc. 2021 Equity Incentive Plan (the “2021 Plan”). Under the 2021 Plan, a total of 4,500,000 4,369,300 The following is a summary of stock option/warrant activity: Schedule of Stock Option and Warrant Activity Weighted Weighted Average Options/ Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2019 1,009,500 3.00 3.58 $ 1,141,500 Granted 775,000 3.00 Forfeited - Exercised - Outstanding, August 31, 2020 1,784,500 2.20 4.09 $ 3,173,800 Granted 2,460,650 3.36 Forfeited - Exercised (7,500 ) 1.60 Outstanding, August 31, 2021 4,237,650 2.89 4.26 $ 218,240 Exercisable, August 31, 2021 4,207,400 $ 2.88 4.25 $ 218,240 The exercise price for options/warrants outstanding at August 31, 2021: Schedule of Options and Warrants Outstanding and Exercisable Outstanding Exercisable Number of Number of Options/ Exercise Options/ Exercise Warrants Price Warrants Price 997,000 $ 1.60 997,000 $ 1.60 775,000 3.00 775,000 3.00 2,388,050 3.35 2,388,050 3.35 72,600 3.80 42,350 3.80 5,000 5.00 5,000 5.00 4,237,650 4,207,400 For options granted during fiscal year ended August 31, 2021 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 3.76 3.80 For options granted during the fiscal year ended August 31, 2020 where the exercise price equaled the stock price at the date of the grant, the weighted-average fair value of such options was $ 2.92 3.00 The fair value of the stock options is being amortized to stock option expense over the vesting period. The Company recorded stock option expense of $ 155,496 2,265,211 111,068 The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows: Schedule of Fair Value of Options Granted by Using Valuation Assumptions Years Ended August 31, 2021 2020 Risk-free interest rate 0.42 % 0.21 % Expected life of the options 2.5 2.5 Expected volatility 268 % 281 % Expected dividend yield 0 % 0 % During the year ended August 31, 2020, the Company re-priced the exercise price of 449,500 1.60 437,000 62,822

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Aug. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 14 – Income Taxes The Company’s Canadian subsidiaries are subject to the income tax laws of the Province of Ontario and the country of Canada. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A full valuation allowance is established against all net deferred tax assets as of August 31, 2021 and 2020 based on estimates of recoverability. While the Company has optimistic plans for its business strategy, it determined that such a valuation allowance was necessary given the current and expected near term losses and the uncertainty with respect to its ability to generate sufficient profits from its business model. The current and deferred income tax expenses for the year ended August 31, 2021 and 2020 were $nil. A reconciliation of the differences between the effective and statutory income tax rates are as follows: Schedule of Effective and Statutory Income Tax Rates Year Ended August 31, 2021 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (1,102,559 ) $ (3,359,588 ) $ (4,462,147 ) Expected income tax benefit (292,178 ) -26.5 % (907,089 ) -27.0 % (1,199,267 ) Stock based compensation - 0.0 % 278,281 8.3 % 278,281 Change in valuation allowance 292,178 26.5 % 628,808 18.7 % 920,986 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2020 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (232,991 ) $ (4,682,163 ) $ (4,915,154 ) Expected income tax benefit (61,743 ) -26.5 % (1,264,184 ) -27.0 % (1,325,927 ) Stock based compensation - 0.0 % 787,869 16.8 % 787,869 Change in valuation allowance 61,743 26.5 % 476,315 10.2 % 538,058 $ - 0.0 % $ - 0.0 % $ - 0.0 % At August 31, 2021 and 2020, the significant components of the deferred tax asset and liability are summarized below: Schedule of the Deferred Tax Assets 2021 2020 Deferred tax asset: Net operating loss carryforwards $ 4,168,876 $ 2,913,805 Total deferred tax asset 4,168,876 2,913,805 Less: valuation allowance (4,168,876 ) (2,913,805 ) Total deferred tax asset - - Deferred tax liability: Intangible assets (1,500,372 ) - Total deferred tax liability (1,500,372 ) - Net deferred tax liability $ (1,500,372 ) $ - The valuation allowance for the years ended August 31, 2021 and 2020 increased by $ 1,255,071 787,060 The Company has recorded as of August 31, 2021 and 2020 a valuation allowance of $ 4,168,876 2,913,805 The Company conducts an analysis of its tax positions and has concluded that it has no uncertain tax positions as of August 31, 2021 and 2020. As of August 31, 2021, the Company has net operating loss carry-forward of approximately $ 5,577,000 5,643,000

Acquisitions

Acquisitions	9 Months Ended	12 Months Ended
Acquisitions	May 31, 2022	Aug. 31, 2021
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Note 16 – Acquisitions Terragenx On November 17, 2021, the Company and NHL, a wholly owned subsidiary of the Company, entered into that certain Share Exchange Agreement (the “Terra SEA”), dated as of November 17, 2021, by and among the Company, NHL, Terragenx Inc. (“Terra”), TMS Inc. (“TMS”), Shawn Mullins, Claude Fournier, and The Coles Optimum Health and Vitality Trust (“COHV” and collectively with TMS, Mr. Mullins and Mr. Fournier, the “Terra Shareholders”). Collectively, the Terra Shareholders owned 91 Pursuant to the terms of the Terra SEA, NHL agreed to purchase from the Terra Shareholders, and the Terra Shareholders agreed to sell to NHL, the Terra Purchased Shares on the closing date, in exchange for payment by NHL of the purchase price (the “Purchase Price”) of CAD$ 500,000 398,050 3.35 The Exchange closed on November 17, 2021. At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 91 100 118,821 91 In addition, the Company will issue 500,000 1.59 983,925 1,521,348 115,427 The business combination accounting is not yet complete and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 29,291 Inventory 42,273 Prepaid expenses and other current assets 398 Property and equipment 66,759 Intangible assets 1,179,361 Accounts payable and accrued expenses (189,080 ) CEBA loan (47,766 ) Minority interest (97,311 ) Purchase price $ 983,925 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 983,925 $ 983,925 The purchase of Terragenx was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented. Mullins Asset Purchase Agreement On November 17, 2021, the Company entered into that certain Asset Purchase Agreement (the “Mullins APA”), dated as of November 17, 2021, by and between the Company and Terence Mullins. Pursuant to the terms of the Mullins APA, Mr. Mullins agreed to sell, and the Company agreed to purchase, all of Mr. Mullins’ right, title and interest in and to certain assets (the “Mullins IP Assets”), in exchange for a purchase price of CAD$ 2,500,000 1,990,250 (a) CAD$ 2,000,000 1,592,200 (b) CAD$ 500,000 398,050 118,821 All shares issued or allotted under the terms and conditions of the Mullins APA are calculated at a value of $ 3.35 1.59 755,701 188,925 In addition, the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales MiTelemed+ On October 8, 2021, the Company and NHL completed a Joint Venture Agreement (the “MiTelemed+ JV”) with EK-Tech Solutions Inc. (“EK-Tech”) to establish the joint venture company MiTelemed+ Inc., an Ontario province Canada corporation (“MiTelemed+”), to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform. At closing, EK-Tech contributed all intellectual property, source code, and core data of the iTelemed platform, valued at CAD$ 1,500,000 185,000 The net profits and net losses of the JV will be split 50/50 between NHL and EK-Tech Share Exchange Agreement to Acquire 50.1 On March 1, 2022, the Company and NHL completed a Share Exchange Agreement (the “1285 SEA”) with 12858461 Canada Corp. (“1285”), a Canada federal corporation in the business of providing clinic-based physiotherapy and related ancillary services and products, and Prashant A. Jani, a Canadian citizen and sole shareholder of 1285 (the “1285 Shareholder”), to acquire 50.1 68,000 17,000 4.00 This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, 1285 had revenues of $ 54,414 15,999 The business combination accounting is not yet complete and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 7,629 Accounts receivable 2,754 Property and equipment 8,813 Goodwill 31,705 Minority interest (25,401 ) Purchase price $ 25,500 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 25,500 $ 25,500 The purchase of 1285 was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented. Asset Purchase Agreement with Poling Taddeo Hovius Physiotherapy Professional Corp., operating as Fairway Physiotherapy and Sports Injury Clinic On March 1, 2022, the Company and NHL completed an Asset Purchase Agreement (the “PTHPC APA”) with Poling Taddeo Hovius Physiotherapy Professional Corp. (“PTHPC”), operating a clinic-based physiotherapy, rehabilitative, and related ancillary services and products business known as Fairway Physiotherapy and Sports Injury Clinic (“FAIR”), and Jason Taddeo, a Canadian citizen and the sole shareholder of PTHPC (the “PTHPC Shareholder”), Under the terms and conditions of the PTHPC APA, PTHPC agreed to sell, assign and transfer to NHL, free and clear of all encumbrances, other than permitted encumbrances, and NHL agreed to purchase from PTHPC all of PTHPC’s right, title and interest in and to all of its assets related to FAIR and the FAIR Business, with the exception of certain limited exclusions, and the rights, privileges, claims and properties of any kind whatsoever that are related thereto, whether owned or leased, real or personal, tangible or intangible, of every kind and description and wheresoever situated. Under the terms and conditions of the PTHPC APA, the purchase price is $ 627,000 156,750 4.00 This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, PTHPC had revenues of $ 118,742 17,619 The business combination accounting is not yet complete and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 18,383 Accounts receivable 44,289 Prepaid expenses and other current assets 11,292 Property and equipment 9,475 Goodwill 151,686 Purchase price $ 235,125 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 235,125 $ 235,125 The purchase of PTHPC was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented. Membership Interest Purchase Agreement with Clinical Consultants International LLC On March 17, 2022, the Company entered into a Membership Interest Purchase Agreement (the “CCI Agreement”) by and among the Company, CCI, each of the members of CCI (the “CCI Members”), and Dr. Joseph Chalil as the representative of the CCI Members. Pursuant to the terms of the CCI Agreement, the parties agreed to enter into a business combination transaction (the “CCI Acquisition”), pursuant to which, among other things, the CCI Members will sell and assign to the Company all of their membership interests of CCI, in exchange for a total of 800,000 100 800,000 This acquisition was considered an acquisition of a business under ASC 805. From the date of acquisition until May 31, 2022, CCI had revenues of $ 0 717 The business combination accounting is not yet complete and the amounts assigned to assets acquired and liabilities assumed are provisional. Therefore, this may result in future adjustments to the provisional amounts as information is obtained about facts and circumstances that existed at the acquisition date. A summary of the preliminary purchase price allocation at fair value is below. Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 2,186 Goodwill 1,701,814 Purchase price $ 1,704,000 The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock 1,704,000 $ 1,704,000 The purchase of CCI was not considered significant for accounting purposes; therefore, pro forma financial statements are not presented.	Note 15 – Acquisitions Acquisition of Assets On December 11, 2020, the Company entered into that certain Asset Purchase Agreement by and between the Company and 2794512 Ontario Inc. (the “Seller”) (the “2794512 APA”), pursuant to which the Company agreed to purchase, and Seller agreed to sell, generic primary and sub-primary drug formulations (known as bioequivalence) of name brand pharmaceutical reference products related to usage as injectables, ophthalmic, and topical applications. Pursuant to the terms of the 2794512 APA, the purchase price is $ 876,000 240,000 3.65 Acquisition of Businesses On May 24, 2021, the Company’s acquired PRO-DIP, LLC, to complement several of the Company’s growth initiatives (i) to build a health science related IP portfolio, and (ii) deliver wellness and preventative healthcare products to the marketplace. This acquisition was considered an acquisition of a business under ASC 805. From the period from the acquisition date to August 31, 2021, PRO-DIP LLC had revenues of $ 1,172 106,706 On May 28, 2021, the Company and NHL entered into a Share Exchange Agreement (the “ACZ SEA”) by and among the Company and NHL, on the one hand, and Acenzia Inc., Avec8 Holdings Inc., Ambour Holdings Inc., Indrajit Sinha, Grant Bourdeau and Derrick Bourdeau, on the other hand (collectively the “ACZ Shareholders”). On June 24, 2021, pursuant to the terms of the ACZ SEA, the acquisition of Acenzia by NHL closed. On October 22, 2021, the parties (i) set the final Purchase Price, as determined by the Post-Closing Purchase Price Adjustment, at a value of $ 14,162,795 3,622,199 3.91 9,236,607 446,390 549,666 A summary of the purchase price allocation for Acenzia and PRO-DIP at fair value is below. Summary of Purchase Price Allocation at Fair Value Acenzia PRO-DIP Cash and cash equivalents $ 3,738,171 $ - Accounts receivable 808,165 - Inventory 195,518 9,050 Prepaid expenses and other current assets 3,594 - Property and equipment 5,687,988 16,355 Intangible assets 6,227,000 455,752 Goodwill 8,726,949 - Accounts payable and accrued expenses (1,845,114 ) - Due to related party (185,614 ) - Note payable (12,534,593 ) (40,320 ) Deferred tax liability (1,536,000 ) - Lease obligation (49,457 ) - Purchase price $ 9,236,607 $ 440,837 The purchase price was paid as follows: Summary of Purchase Price Acenzia PRO-DIP Cash $ - $ 10,000 Issuance of common stock - 430,837 Common stock to be issued 9,236,607 - $ 9,236,607 $ 440,837 The following are the unaudited pro forma results of operations for the years ended August 31, 2021 and 2020, as if Acenzia and PRO-DIP had been acquired on September 1, 2019. The pro forma results include estimates and assumptions which management believes are reasonable. However, pro forma results do include any anticipated cost savings or other effects of the planned integration of these entities, and are not necessarily indicative of the results that would have occurred if the business combination had been in effect on the dates indicated. Summary of Unaudited Pro Forma Results of Operations 2021 2020 Pro Forma Combined Financials (unaudited) Years Ended August 31, 2021 2020 Sales $ 12,860,406 $ 14,047,859 Cost of goods sold 8,231,486 8,420,513 Gross profit 4,628,920 5,627,346 Operating expenses 10,285,972 14,091,463 Loss from operations (5,657,052 ) (8,464,117 ) Net loss (6,335,783 ) (9,421,409 ) Loss per share (0.22 ) (0.35 )

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
Commitments and Contingencies	May 31, 2022	Aug. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time-to-time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our condensed consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s unaudited condensed consolidated financial position as of May 31, 2022, results of operations, cash flows or liquidity of the Company.	Note 16 – Commitments and Contingencies Litigation The Company is party to certain legal proceedings from time to time incidental to the conduct of its business. These proceedings could result in fines, penalties, compensatory or treble damages or non-monetary relief. The nature of legal proceedings is such that the Company cannot assure the outcome of any particular matter, and an unfavorable ruling or development could have a materially adverse effect on our consolidated financial position, results of operations and cash flows in the period in which a ruling or settlement occurs. However, based on information available to the Company’s management to date, the Company’s management does not expect that the outcome of any matter pending against the Company is likely to have a materially adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity.

Segment Reporting

Segment Reporting	9 Months Ended	12 Months Ended
Segment Reporting	May 31, 2022	Aug. 31, 2021
Segment Reporting [Abstract]
Segment Reporting	Note 17 – Segment Reporting ASC Topic 280, Segment Reporting The following tables summarize the Company’s segment information for the three and nine months ended May 31, 2022 and 2021: Schedule of Segment Reporting Information Healthcare services $ - $ - $ - $ - Three Months Ended May 31, Nine Months Ended May 31, 2022 2021 2022 2021 Sales Healthcare services $ 2,199,889 $ 2,380,974 $ 6,253,089 $ 6,612,374 Product sales 11,651,994 - 13,629,944 - Corporate - - - - $ 13,851,883 $ 2,380,974 $ 19,883,033 $ 6,612,374 Gross profit Healthcare services $ 939,542 $ 1,280,458 $ 2,499,608 $ 2,843,354 Product sales 1,469,340 - 2,392,094 - Corporate - - - - $ 2,408,882 $ 1,280,458 $ 4,891,702 $ 2,843,354 Income (loss) from operations Healthcare services $ (239,981 ) $ 255,129 $ (616,303 ) $ (99,454 ) Product sales 336,348 - (509,342 ) - Corporate (1,299,113 ) (657,101 ) (3,561,436 ) (2,386,186 ) $ (1,202,746 ) $ (401,972 ) $ (4,687,081 ) $ (2,485,640 ) Depreciation and amortization Healthcare services $ 249,831 $ 13,902 $ 393,942 $ 57,840 Product sales 266,166 - 852,692 - Corporate 367,600 367,600 1,102,800 1,061,085 Depreciation and amortization $ 881,597 $ 381,502 $ 2,349,434 $ 1,118,925 Capital expenditures Healthcare services $ - $ 200,751 $ 175,418 $ 201,369 Product sales - - 15,555 - Corporate - - - - Capital expenditures $ - $ 200,751 $ 190,973 $ 201,369 Interest expenses Healthcare services $ 14,532 $ 21,701 $ 54,686 $ 68,590 Product sales 94,765 - 1,067,211 - Corporate 404,101 - 686,413 - Interest expenses $ 513,398 $ 21,701 $ 1,808,310 $ 68,590 Net loss Healthcare services $ (252,122 ) $ 235,867 $ (663,646 ) $ (160,492 ) Product sales (21,153 ) - (2,641,091 ) - Corporate (3,470,750 ) (651,138 ) (7,123,887 ) (2,368,473 ) Net income (loss) $ (3,744,025 ) $ (415,271 ) $ (10,428,624 ) $ (2,528,965 ) Healthcare services $ - $ - As of As of May 31, August 31, 2022 2021 Total assets Healthcare services $ 6,491,538 $ 7,318,888 Product sales 24,830,711 21,427,285 Corporate 40,470,565 33,212,108 Total assets $ 71,792,814 $ 61,958,281 Accounts receivable Healthcare services $ 815,833 $ 953,919 Product sales 1,764,474 514,510 Corporate 2,585,932 - Accounts receivable $ 5,166,239 $ 1,468,429 Intangible assets Healthcare services $ - $ - Product sales 7,224,895 5,958,736 Corporate 24,967,963 26,070,763 Intangible assets $ 32,192,858 $ 32,029,499 Goodwill Healthcare services $ 741,209 $ 557,357 Product sales 8,923,595 8,931,491 Corporate 1,701,814 - Goodwill $ 11,366,618 $ 9,488,848	Note 17 – Segment Reporting ASC Topic 280, Segment Reporting two The following tables summarize the Company’s segment information for the years ended August 31, 2021 and 2020: Schedule of Segment Reporting Information Years Ended August 31, 2021 2020 Sales Healthcare services $ 8,857,693 $ 7,860,567 Product manufacturing and development 447,562 - Corporate - - $ 9,305,255 $ 7,860,567 Gross profit Healthcare services $ 3,694,512 $ 3,058,372 Product manufacturing and development 128,486 - Corporate - - $ 3,822,998 $ 3,058,372 Income (loss) from operations Healthcare services $ (516,437 ) $ 442,656 Product manufacturing and development (580,523 ) - Corporate (3,276,559 ) (4,705,254 ) $ (4,373,519 ) $ (4,262,598 ) Depreciation and amortization Healthcare services $ 91,978 $ 75,726 Product manufacturing and development 203,459 - Corporate 1,428,685 1,369,350 $ 1,724,122 $ 1,445,076 Capital expenditures Healthcare services $ 216,284 $ 12,110 Product manufacturing and development 39,665 - Corporate - - $ 255,949 $ 12,110 Interest expenses Healthcare services $ 89,154 $ 156,662 Product manufacturing and development 75,849 - Corporate - - $ 165,003 $ 156,662 Net loss Healthcare services $ (552,893 ) $ (232,991 ) Product manufacturing and development (656,372 ) - Corporate (3,252,882 ) (4,682,163 ) $ (4,462,147 ) $ (4,915,154 ) As of August 31, 2021 2020 Total assets Healthcare services $ 7,318,888 $ 7,607,820 Product manufacturing and development 21,427,285 - Corporate 33,212,108 27,782,798 $ 61,958,281 $ 35,390,618 Accounts receivable Healthcare services $ 953,919 $ 1,732,432 Product manufacturing and development 514,510 - Corporate - - $ 1,468,429 $ 1,732,432 Intangible assets Healthcare services $ - $ - Product manufacturing and development 6,365,705 - Corporate 26,070,763 26,623,448 $ 32,436,468 $ 26,623,448 Goodwill Healthcare services $ 557,357 $ 636,942 Product manufacturing and development 8,524,522 - Corporate - - $ 9,081,879 $ 636,942 All of the property and equipment except for $ 16,355

Subsequent Events

Subsequent Events	9 Months Ended	12 Months Ended
Subsequent Events	May 31, 2022	Aug. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 18 – Subsequent Events Promissory Notes Payment On June 1, 2022, the Company paid the balance owed on one of two Terragenx $ 1.875 948,874 Promissory Notes Payment and Extension On June 1, 2022, the Company made a partial payment on principal and interest owed on one of two Terragenx $ 1.875 192,188 November 29, 2022 937,500 Promissory Note Amortization Payment On June 14, 2022, the Company made a cash payment in the aggregate amount of $ 1,391,589 Payment pursuant to the terms and conditions of the $16.66m+ convertible notes Dalcourt and Gaynor Board of Directors Compensation On June 29, 2022, the Board granted Pierre Dalcourt 250,000 5 On June 29, 2022, the Board granted Michael Gaynor 50,000 5 BOD and Committee Changes Effective June 30, 2022, Robert Oliva, Michael Gaynor and Pierre Dalcourt resigned as members of the Board of Directors. Also, effective June 30, 2022, (i) Sarfaraz Ali was appointed as a member of the Board of Directors; (ii) the size of the Board of Directors was reduced from seven to five members. The Board of Directors has undertaken a review of Mr. Ali’s independence and determined that Mr. Ali does not have a material relationship with the Company that could compromise his ability to exercise independent judgment in carrying out his responsibilities and that Mr. Ali is “independent” as that term is defined under the listing standards of The Nasdaq Stock Market LLC 75,000 Robert Mattacchione Christopher David Alex Flesias Michael Pope Sarfaraz Ali Effective June 30, 2022, the Board of Directors appointed Mr. Ali to serve as a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. As of June 30, 2022, the Board committee chairs and members are as follows: Audit Committee Compensation Committee Nominating and Corporate Governance Committee Michael Pope Chair Member Member Sarfaraz Ali Member Chair Member Alex Flesias Member Member Chair Promissory Note Payment On June 30, 2022, the Company paid the balance owed on an Acenzia promissory note for an aggregate payment of $ 5,300,000 Restricted Stock Issuance for Independent Contractor Agreement On July 5, 2022, the Company issued 50,000 Promissory Note Conversion On December 14, 2021, the Company issued to certain accredited institutional investors senior secured convertible notes, which notes are convertible into shares of the Company’s common stock, under certain conditions. On July 12, 2022, a note holder converted $ 25,000 143 12,572	Note 18 – Subsequent Events 2021 Plan Option Grant On October 1, 2021, the Company granted 48,000 1.87 October 1, 2026 MiTelemed+ On October 8, 2021, the Company and NHL completed a Joint Venture Agreement (the “MiTelemed+ JV”) with EK-Tech Solutions Inc. (“EK-Tech”) to establish the joint venture company MiTelemed+ Inc., an Ontario province Canada corporation (“MiTelemed+”), to operate, support, and expand access and functionality of EK-Tech’s enhanced proprietary Telehealth platform. At closing, EK-Tech contributed all intellectual property, source code, and core data of the iTelemed platform, valued at CAD$ 1,500,000 185,000 The net profits and net losses of the JV will be split 50/50 between NHL and EK-Tech. Terragenx Share Exchange On November 17, 2021, the Company and NHL, a wholly owned subsidiary of the Company, entered into that certain Share Exchange Agreement (the “Terra SEA”), dated as of November 17, 2021, by and among the Company, NHL, Terragenx Inc. (“Terra”), TMS Inc. (“TMS”), Shawn Mullins, Claude Fournier, and The Coles Optimum Health and Vitality Trust (“COHV” and collectively with TMS, Mr. Mullins and Mr. Fournier, the “Terra Shareholders”). Collectively, the Terra Shareholders owned 91% Pursuant to the terms of the Terra SEA, NHL agreed to purchase from the Terra Shareholders, and the Terra Shareholders agreed to sell to NHL, the Terra Purchased Shares on the closing date, in exchange for payment by NHL of the purchase price (the “Purchase Price”) of CAD$ 500,000 398,050 3.35 The Exchange closed on November 17, 2021. At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 91% 100 118,821 91% Mullins Asset Purchase Agreement On November 17, 2021, the Company entered into that certain Asset Purchase Agreement (the “Mullins APA”), dated as of November 17, 2021, by and between the Company and Terence Mullins. Pursuant to the terms of the Mullins APA, Mr. Mullins agreed to sell, and the Company agreed to purchase, all of Mr. Mullins’ right, title and interest in and to certain assets (the “Mullins IP Assets”), in exchange for a purchase price of CAD$ 2,500,000 1,990,250 (a) CAD$ 2,000,000 1,592,200 (b) CAD$ 500,000 398,050 118,821 All shares issued or allotted under the terms and conditions of the Mullins APA are calculated at a value of $ 3.35 In addition, the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales Jefferson Street Capital Stock Purchase Agreement & Secured Convertible Promissory Note On November 17, 2021, the Company and Terra entered into that certain securities purchase agreement (the “Jefferson SPA”), dated as of November 17, 2021, by and among the Company, Terra and Jefferson Street Capital LLC (“Jefferson”). Pursuant to the terms of the Jefferson SPA, (i) the Company agreed to issue and sell to Jefferson the Jefferson Note (as hereinafter defined); (ii) the Company agreed to issue to Jefferson the Jefferson Warrant (as hereinafter defined); and (iii) the Company agreed to issue to Jefferson 1,000,000 750,000 Pursuant to the terms of the Jefferson SPA, on November 17, 2021 May 17, 2022 937,500 937,500 750,000 187,500 1% Any amount of principal, interest or other amount due on the Jefferson Note that is not paid when due will bear interest at the rate of the lesser of (i) 12%, or (b) the maximum rate allowed by law. Jefferson may, at any time, convert all or any portion of the then outstanding and unpaid principal amount and interest into shares of the Company’s common stock at a conversion price of $ 3.35 On November 17, 2021, Jefferson paid the Jefferson Purchase Price of $ 750,000 Terra may prepay the Jefferson Note at any time in accordance with the terms of the Jefferson Note. Except as related to the next transaction after the issue date of the Jefferson Note conducted on the Company’s behalf by the Maxim Group LLC, Terra and the Company agreed to pay to Jefferson on an accelerated basis, any outstanding Principal Amount of the Jefferson Note, along with all unpaid interest, and fees and penalties, if any, from the sources of capital below, at Jefferson’s discretion, it being acknowledged and agreed by Jefferson that the Company and Terra have the right to make bona fide payments to vendors with Company common stock: ● At Jefferson’s option, 15% of the net cash proceeds of any future financings by the Company, Terra or any subsidiary, whether debt or equity, or any other financing proceeds such as cash advances, royalties or earn-out payments. ● All net proceeds from any sale of assets of the Company, Terra or any subsidiaries other than sales of inventory in the ordinary course of business or receipt by the Company or any subsidiaries of any tax credits or collections pursuant to any settlement or judgement. ● Net proceeds resulting from the sale of any assets outside of the ordinary course of business or securities in any subsidiary. Jefferson Street Capital Common Stock Purchase Warrant Also on November 17, 2021, pursuant to the terms of the Jefferson SPA, the Company issued to Jefferson a common stock purchase warrant (the “Jefferson Warrant”) for the purchase of 111,940 3.35 Platinum Point Capital Stock Purchase Agreement & Secured Convertible Promissory Note On November 17, 2021, the Company and Terra entered into that certain securities purchase agreement (the “Platinum SPA”), dated as of November 17, 2021, by and among the Company, Terra and Platinum Point Capital LLC (“Platinum”). Pursuant to the terms of the Platinum SPA, (i) the Company agreed to issue and sell to Platinum the Platinum Note (as hereinafter defined); (ii) the Company agreed to issue to Platinum the Platinum Warrant (as hereinafter defined); and (iii) the Company agreed to issue to Platinum 1,000,000 750,000 Pursuant to the terms of the Platinum SPA, on November 17, 2021 May 17, 2022 937,500 937,500 750,000 187,500 1% Any amount of principal, interest or other amount due on the Platinum Note that is not paid when due will bear interest at the rate of the lesser of (i) 12%, or (b) the maximum rate allowed by law. Platinum may, at any time, convert all or any portion of the then outstanding and unpaid principal amount and interest into shares of the Company’s common stock at a conversion price of $ 3.35 On November 17, 2021, Platinum paid the Platinum Purchase Price of $ 750,000 Terra may prepay the Platinum Note at any time in accordance with the terms of the Platinum Note. Except as related to the next transaction after the issue date of the Platinum Note conducted on the Company’s behalf by the Maxim Group LLC, Terra and the Company agreed to pay to Platinum on an accelerated basis, any outstanding Principal Amount of the Platinum Note, along with all unpaid interest, and fees and penalties, if any, from the sources of capital below, at Platinum’s discretion, it being acknowledged and agreed by Platinum that the Company and Terra have the right to make bona fide payments to vendors with Company common stock: ● At Platinum’s option, 15% of the net cash proceeds of any future financings by the Company, Terra or any subsidiary, whether debt or equity, or any other financing proceeds such as cash advances, royalties or earn-out payments. ● All net proceeds from any sale of assets of the Company, Terra or any subsidiaries other than sales of inventory in the ordinary course of business or receipt by the Company or any subsidiaries of any tax credits or collections pursuant to any settlement or judgement. ● Net proceeds resulting from the sale of any assets outside of the ordinary course of business or securities in any subsidiary. Platinum Point Capital Common Stock Purchase Warrant Also on November 17, 2021, pursuant to the terms of the Platinum SPA, the Company issued to Platinum a common stock purchase warrant (the “Platinum Warrant”) for the purchase of 111,940 3.35 December 2021 Registered Direct Offering On December 14, 2021, the Company entered into a Securities Purchase Agreement with an accredited institutional investor (the “Purchaser”) pursuant to which the Company agreed to issue to the Purchaser and the Purchaser agreed to purchase (the “Purchase”), in a registered direct offering, (i) $ 16,666,666 5,833,334 68,557,248 5,833,334 The Notes have an original issue discount of 10% 15,000,000 5% June 14, 2023 1,388,888 2.00 9.99% If an event of default occurs, the holder may convert all, or any part, of the principal amount of a Note and all accrued and unpaid interest and late charge at an alternate conversion price, as described in the Notes. Subject to certain conditions, the Company has the right to redeem all, but not less than all, of the remaining principal amount of the Notes and all accrued and unpaid interest and late charges in cash at a price equal to 135% of the amount being redeemed. The Warrants are exercisable at an exercise price of $ 2.00

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
Convertible Notes Payable	May 31, 2022
Convertible Notes Payable
Convertible Notes Payable	Note 11 – Convertible Notes Payable Novo Integrated On December 14, 2021, Novo Integrated issued two convertible notes payable for a total of $ 16,666,666 8,333,333 5 June 14, 2023 2.00 In connection with the $16.66m+ convertible notes, the Company issued the note holders warrants to purchase a total of 5,833,334 2.00 The warrants expire on December 14, 2025. The Company first determined the value of the $16.66m+ convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $ 7,680,156 ● Expected life of 4.0 ● Volatility of 275 ● Dividend yield of 0 ● Risk free interest rate of 1.23 The face amount of the $16.66m+ convertible notes of $ 16,666,666 was proportionately allocated to the $16.66m+ convertible notes and the warrants in the amount of $ 11,409,200 and $ 5,257,466 , respectively. The amount allocated to the warrants of $ 5,257,466 was recorded as a discount to the convertible note and as additional paid in capital. The $16.66m+ convertible notes contained an original issue discount totaling $ 1,666,666 and the Company also incurred $ 1,140,000 in loan fees in connection with the $16.66m+ convertible notes. The combined total discount is $ 8,064,132 and will be amortized over the life of the $16.66m+ convertible notes. During the nine months ended May 31, 2022, the Company amortized $ 2,893,927 of the debt discount and as May 31, 2022, the unamortized debt discount was $ 5,170,205 . During the three months ended May 31, 2022, an aggregate of $ 1,244,444 3,405 623,929 Terragenx On November 17, 2021, Terragenx, a 91 1,875,000 937,500 1 May 17, 2022 3.35 In connection with the $1.875m convertible notes, the Company issued the note holders warrants to purchase a total of 223,880 3.35 The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $ 351,240 ● Expected life of 3.0 ● Volatility of 300 ● Dividend yield of 0 ● Risk free interest rate of 0.85 The face amount of the $1.875m convertible notes of $ 1,875,000 1,579,176 295,824 295,824 375,000 90,000 760,824 760,824 0

Summary of Significant Accoun_2

Organization and Basis of Pre_2

Organization and Basis of Presentation (Tables)	9 Months Ended	12 Months Ended
Organization and Basis of Presentation (Tables)	May 31, 2022	Aug. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Foreign Currency Translation, Exchange Rate Used	Schedule of Foreign Currency Translation, Exchange Rate Used May 31, 2022 May 31, 2021 August 31, 2021 Period end: CAD to USD exchange rate $ 0.7910 $ 0.8284 $ 0.7917 Average period: CAD to USD exchange rate $ 0.7897 $ 0.7834 $ 0.7885	Schedule of Foreign Currency Translation, Exchange Rate Used August 31, August 31, 2021 2020 Period end: CAD to USD exchange rate $ 0.7917 $ 0.7674 Average period: CAD to USD exchange rate $ 0.7885 $ 0.7435

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
Summary of Significant Accounting Policies (Tables)	May 31, 2022	Aug. 31, 2021
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Assets	Schedule of Estimated Useful Lives of Assets Building 30 Leasehold improvements 5 Clinical equipment 5 Computer equipment 3 Office equipment 5 Furniture and fixtures 5	Schedule of Estimated Useful Lives of Assets Building 30 years Leasehold improvements 5 years Clinical equipment 5 years Computer equipment 3 years Office equipment 5 years Furniture and fixtures 5 years
Schedule of Intangible Assets Amortized Estimated Useful Lives	The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 Software license 7 Intellectual property 7 Customer relationships 5 Brand names 7	The Company’s intangible assets are being amortized over their estimated useful lives as follows: Schedule of Intangible Assets Amortized Estimated Useful Lives Land use rights 50 years Software license 7 years Intellectual property 7 years Customer relationships 5 years Brand names 7 years Workforce 5 years
Schedule of Changes in Goodwill		Summary of changes in goodwill by acquired businesses is as follows: Schedule of Changes in Goodwill APKA EFL Rockland Acenzia Total Balance, August 31, 2019 $ 187,675 $ 217,703 $ 217,703 $ - $ 623,081 Foreign currency translation adjustment 4,175 4,843 4,843 - 13,861 Balance, August 31, 2020 191,850 222,546 222,546 - 636,942 Goodwill acquired with purchase of business - - - 8,726,949 8,726,949 Impairment of goodwill - (99,593 ) - - (99,593 ) Foreign currency translation adjustment 6,075 6,886 7,047 (202,427 ) (182,419 ) Balance, August 31, 2021 $ 197,925 $ 129,839 $ 229,593 $ 8,524,522 $ 9,081,879

Inventory (Tables)

Inventory (Tables)	9 Months Ended	12 Months Ended
Inventory (Tables)	May 31, 2022	Aug. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Inventory May 31, August 31, 2022 2021 Raw materials $ 1,162,067 $ 1,017,566 Work in process 144,500 144,628 Finished Goods 404,273 243,912 Inventory Gross 1,710,840 1,406,106 Allowance for slow moving and obsolete inventory (1,065,777 ) (1,066,721 ) Inventory, net $ 645,063 $ 339,385	Inventory at August 31, 2021 and 2020 consisted of the following: Schedule of Inventory 2021 2020 Raw materials $ 1,017,566 $ - Work in process 144,628 - Finished Goods 243,912 - Inventory, Gross 1,406,106 - Allowance for slow moving and obsolete inventory (1,066,721 ) - Inventory, net $ 339,385 $ -

Accounts Receivables, net (Tabl

Accounts Receivables, net (Tables)	9 Months Ended	12 Months Ended
Accounts Receivables, net (Tables)	May 31, 2022	Aug. 31, 2021
Receivables [Abstract]
Schedule of Accounts Receivables, Net	Accounts receivables, net at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Accounts Receivables, Net May 31, August 31, 2022 2021 Trade receivables $ 5,739,193 $ 2,411,499 Amounts earned but not billed 132,430 154,558 Accounts receivable gross 5,871,623 2,566,057 Allowance for doubtful accounts (705,384 ) (1,097,628 ) Accounts receivable, net $ 5,166,239 $ 1,468,429	Accounts receivables, net at August 31, 2021 and 2020 consisted of the following: Schedule of Accounts Receivables, Net 2021 2020 Trade receivables $ 2,411,499 $ 1,948,520 Amounts earned but not billed 154,558 301,943 Accounts receivable, Gross 2,566,057 2,250,463 Allowance for doubtful accounts (1,097,628 ) (518,031 ) Accounts receivable, net $ 1,468,429 $ 1,732,432

Other Receivables (Tables)

Other Receivables (Tables)	9 Months Ended	12 Months Ended
Other Receivables (Tables)	May 31, 2022	Aug. 31, 2021
Receivables [Abstract]
Schedule of Other Receivables	Other receivables at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Other Receivables May 31, August 31, 2022 2021 Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8 March 1, 2019 $ - $ 296,888 Advance to corporation; accrues interest at 12 January 31, 2023 79,100 79,170 Advance to corporation; accrues interest at 10 May 1, 2023 225,924 225,924 Advance to corporation; accrues interest at 12 August 1, 2022 508,613 509,063 Advance to corporation; accrues interest at 10 September 1, 2022 395,500 395,850 Total other receivables 1,209,137 1,506,895 Current portion (1,209,137 ) (814,157 ) Long-term portion $ - $ 692,738	Other receivables at August 31, 2021 and 2020 consisted of the following: Schedule of Other Receivables 2021 2020 296,888 287,775 Notes receivable dated April 1, 2015 and amended on May 23, 2017; accrued interest at 8% March 1, 2019 $ 296,888 $ 287,775 Advance to corporation; accrues interest at 12% December 31, 2021 79,170 76,740 Advance to corporation; accrues interest at 10% March 1, 2022 225,924 225,924 Advance to corporation; accrues interest at 12% February 1, 2022 509,063 - Advance to corporation; accrues interest at 10% September 1, 2022 395,850 - Total other receivables 1,506,895 590,439 Current portion (814,157 ) (302,664 ) Long-term portion $ 692,738 $ 287,775

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended	12 Months Ended
Property and Equipment (Tables)	May 31, 2022	Aug. 31, 2021
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Property and Equipment May 31, August 31, 2022 2021 Land $ 474,600 $ 475,020 Building 3,559,500 3,562,650 Leasehold improvements 861,188 691,318 Clinical equipment 1,973,582 1,875,537 Computer equipment 27,116 24,679 Office equipment 49,842 46,510 Furniture and fixtures 40,983 41,019 Property and equipment gross 6,986,811 6,716,733 Accumulated depreciation (1,055,128 ) (646,442 ) Total $ 5,931,683 $ 6,070,291	Property and equipment at August 31, 2021 and 2020 consisted of the following: Schedule of Property and Equipment 2021 2020 Land $ 475,020 $ - Building 3,562,650 - Leasehold improvements 691,318 465,857 Clinical equipment 1,875,537 301,337 Computer equipment 24,679 23,921 Office equipment 46,510 29,229 Furniture and fixtures 41,019 39,760 6,716,733 860,104 Accumulated depreciation (646,442 ) (506,444 ) Total $ 6,070,291 $ 353,660

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended	12 Months Ended
Intangible Assets (Tables)	May 31, 2022	Aug. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Intangible Assets May 31, August 31, 2022 2021 Land use rights $ 21,600,000 $ 21,600,000 Software license 1,144,798 1,144,798 Intellectual property 11,495,963 9,388,065 Customer relationships 786,608 787,304 Brand names 2,064,115 2,065,941 37,091,484 34,986,108 Accumulated amortization (4,898,626 ) (2,956,609 ) Total $ 32,192,858 $ 32,029,499	Intangible assets at August 31, 2021 and 2020 consisted of the following: Schedule of Intangible Assets 2021 2020 Land use rights $ 21,600,000 $ 21,600,000 Software license 1,144,798 1,144,798 Intellectual property 9,388,065 5,248,000 Customer relationships 787,304 - Brand names 2,065,941 - Assembled workforce 421,003 - 35,407,111 27,992,798 Accumulated amortization (2,970,643 ) (1,369,350 ) Total $ 32,436,468 $ 26,623,448
Schedule of Expected Amortization Expense of Intangible Assets	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of Intangible Assets Twelve Months Ending May 31, 2023 $ 2,690,018 2024 2,690,018 2025 2,690,018 2026 2,662,926 2027 2,115,863 Thereafter 19,344,015 Total $ 32,192,858	Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows: Schedule of Expected Amortization Expense of Intangible Assets 2022 $ 2,473,490 Years Ending August 31, 2022 $ 2,473,490 2023 2,473,490 2024 2,473,490 2025 2,473,490 2026 2,379,029 Thereafter 20,163,479 Total $ 32,436,468
Schedule of Software Deliverables and Payments		Schedule of Software Deliverables and Payments Cloud DX deliverable Novo payment (terms: Net 15) Heart Friendly Program launches in Clinic #1 CAD$ 50,000 37,929 Novo-branded Android app delivered as APK file CAD$ 35,000 26,550 Novo-branded Clinical portal website delivered CAD$ 35,000 26,550 Pulsewave PAD-1A devices – 1 st CAD$ 20,000 15,171 Marketing services / materials delivered CAD$ 25,000 18,964 Cloud DX hires dedicated Novo support FTE CAD$ 85,000 64,478

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
Accrued Expenses (Tables)	May 31, 2022	Aug. 31, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Accrued Expenses May 31, August 31, 2022 2021 Accrued liabilities $ 1,023,005 $ 811,660 Accrued payroll 182,231 279,018 Unearned revenue 38,556 38,631 Accrued expenses $ 1,243,792 $ 1,129,309	Accrued expenses at August 31, 2021 and 2020 consisted of the following: Schedule of Accrued Expenses 2021 2020 Accrued liabilities $ 811,660 $ 37,457 Accrued payroll 279,018 117,823 Unearned revenue 38,631 39,428 Accrued expenses $ 1,129,309 $ 194,708

Government Loans and Note Pay_2

Government Loans and Note Payable and Government Subsidy (Tables)	9 Months Ended	12 Months Ended
	May 31, 2022	Aug. 31, 2021
Government Loans And Note Payable And Government Subsidy
Schedule of Governmental Loans and Note Payable	Notes payable at May 31, 2022 and August 31, 2021 consisted of the following: Schedule of Governmental Loans and Note Payable May 31, August 31, 2022 2021 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 94,920 63,336 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75 monthly 190 40,320 40,320 Note payable dated December 3, 2019; accrues interest at 3 June 30, 2022 5,252,749 5,069,858 Note payable dated December 3, 2018; accrues interest at 4.53 annual 4,000 December 31, 2028 30,712 30,739 Note payable dated June 24, 2021; accrues interest at 9 950,000 June 24, 2022 - 4,415,000 Total government loans and notes payable 5,418,701 9,619,253 Less current portion (5,260,056 ) (4,485,649 ) Long-term portion $ 158,645 $ 5,133,604 (A) The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 63,280 If the loan amount is paid on or before December 31, 2023, 25 75 60,000 20,000 31,640	Governmental loans and note payable at August 31, 2021 and 2020 consisted of the following: Schedule of Governmental Loans and Note Payable 2021 2020 Note payable issued under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The loan has terms of 24 months and accrues interest at 1% $ - $ 21,900 Note payable issued under the Paycheck Protection Program of the Coronavirus Aid, Relief and Economic Security (“CARES”) Act. The loan has terms of 24 months 1% $ - $ 21,900 Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A). 63,336 61,392 Note payable to the Small Business Administration (“SBA”). The note bears interest at 3.75% monthly 190 40,320 - Note payable dated December 3, 2019; accrues interest at 3% June 30, 2022 5,069,858 - Note payable dated December 3, 2018; accrues interest at 4.53% annual 4,000 December 2, 2028 30,739 - Note payable dated June 24, 2021; accrues interest at 9% 950,000 June 24, 2022 4,415,000 - Total government loans and notes payable 9,619,253 83,292 Less current portion (4,485,649 ) (83,292 ) Long-term portion $ 5,133,604 $ - (A) The Government of Canada launched the Canada Emergency Business Account loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 63,336 December 31, 2022 If the loan amount is paid on or before December 31, 2022, 25%
Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable	Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable Twelve Months Ending May 31, 2023 $ 5,260,056 2024 99,822 2025 5,343 2026 5,790 2027 6,244 Thereafter 41,446 Total $ 5,418,701	Future scheduled maturities of outstanding government loans and notes payable are as follows: Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable 2022 $ 4,485,649 Years Ending August 31, 2022 $ 4,485,649 2023 5,074,763 2024 5,346 2025 5,793 2026 6,247 Thereafter 41,455 Total $ 9,619,253

Leases (Tables)

Leases (Tables)	9 Months Ended	12 Months Ended
Leases (Tables)	May 31, 2022	Aug. 31, 2021
Leases
Schedule of Lease Related Assets and Liabilities	The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of May 31, 2022 and August 31, 2021: Schedule of Lease Related Assets and Liabilities May 31, August 31, 2022 2021 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,222,970 $ 2,543,396 Total lease assets $ 2,222,970 $ 2,543,396 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 544,690 $ 530,797 Noncurrent liabilities Operating lease liability Long-term operating lease liability 1,734,790 2,057,805 Total lease liability $ 2,279,480 $ 2,588,602	The table below presents the lease related assets and liabilities recorded on the Company’s consolidated balance sheets as of August 31, 2021 and 2020: Schedule of Lease Related Assets and Liabilities 2021 2020 Classification on Balance Sheet Assets Operating lease assets Operating lease right of use assets $ 2,543,396 $ 2,810,556 Total lease assets $ 2,543,396 $ 2,810,556 Liabilities Current liabilities Operating lease liability Current operating lease liability $ 530,797 $ 563,793 Noncurrent liabilities Operating lease liability Long-term operating lease liability 2,057,805 2,266,887 Total lease liability $ 2,588,602 $ 2,830,680
Schedule of Lease Obligations	Future minimum operating lease payments are as follows: Schedule of Lease Obligations Twelve Months Ending May 31, 2023 $ 707,309 2024 491,435 2025 406,221 2026 379,585 2027 378,902 Thereafter 464,438 Total payments 2,827,890 Amount representing interest (548,410 ) Lease obligation, net 2,279,480 Less lease obligation, current portion (544,690 ) Lease obligation, long-term portion $ 1,734,790	Lease obligations at August 31, 2021 consisted of the following: Schedule of Lease Obligations Years Ending August 31, 2022 $ 717,772 2023 649,974 2024 444,301 2025 366,620 2026 351,434 Thereafter 728,841 Total payments 3,258,942 Amount representing interest (670,340 ) Lease obligation, net 2,588,602 Less lease obligation, current portion (530,797 ) Lease obligation, long-term portion $ 2,057,805
Schedule of Finance Leases	The net book value of equipment under finance leases included in property and equipment on the accompanying condensed consolidated balance sheets at May 31, 2022 and August 31, 2021 is as follows: Schedule of Finance Leases May 31, August 31, 2022 2021 Cost $ 209,457 $ 209,457 Accumulated amortization (178,383 ) (136,491 ) Net book value $ 31,074 $ 72,966	The net book value of equipment under finance leases included in property and equipment on the accompanying balance sheet at August 31, 2021 is as follows: Schedule of Finance Leases Cost $ 209,457 Accumulated amortization (136,491 ) Net book value $ 72,966
Schedule of Future Minimum Lease Payments	Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Twelve Months Ending May 31, 2023 $ 16,631 2024 8,092 Total payments 24,723 Amount representing interest (178 ) Lease obligation, net 24,545 Less lease obligation, current portion (15,982 ) Lease obligation, long-term portion $ 8,563	Future minimum finance lease payments are as follows: Schedule of Future Minimum Lease Payments Years Ending August 31, 2022 $ 25,153 2023 9,719 2024 5,669 Total payments 40,541 Amount representing interest (1,140 ) Lease obligation, net 39,401 Less lease obligation, current portion (23,184) Lease obligation, long-term portion $ 16,217

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended	12 Months Ended
Stockholders’ Equity (Tables)	May 31, 2022	Aug. 31, 2021
Equity [Abstract]
Schedule of Stock Option and Warrant Activity	The following is a summary of stock options activity: Schedule of Stock Option and Warrant Activity Weighted Weighted Average Average Remaining Aggregate Options Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 1,849,600 2.29 3.14 $ 218,240 Granted 329,985 1.41 Forfeited - Exercised - Outstanding, May 31, 2022 2,179,585 2.16 2.74 $ 658,069 Exercisable, May 31, 2022 1,968,096 $ 2.25 2.52 $ 505,797	The following is a summary of stock option/warrant activity: Schedule of Stock Option and Warrant Activity Weighted Weighted Average Options/ Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2019 1,009,500 3.00 3.58 $ 1,141,500 Granted 775,000 3.00 Forfeited - Exercised - Outstanding, August 31, 2020 1,784,500 2.20 4.09 $ 3,173,800 Granted 2,460,650 3.36 Forfeited - Exercised (7,500 ) 1.60 Outstanding, August 31, 2021 4,237,650 2.89 4.26 $ 218,240 Exercisable, August 31, 2021 4,207,400 $ 2.88 4.25 $ 218,240
Schedule of Options and Warrants Outstanding and Exercisable	The exercise price for stock options outstanding at May 31, 2022: Schedule of Options and Warrants Outstanding and Exercisable Outstanding Exercisable Number of Exercise Number of Exercise Options Price Options Price 281,985 $ 1.33 70,496 $ 1.33 997,000 1.60 997,000 1.60 48,000 1.87 48,000 1.87 775,000 3.00 775,000 3.00 72,600 3.80 72,600 3.80 5,000 5.00 5,000 5.00 2,179,585 1,968,096	The exercise price for options/warrants outstanding at August 31, 2021: Schedule of Options and Warrants Outstanding and Exercisable Outstanding Exercisable Number of Number of Options/ Exercise Options/ Exercise Warrants Price Warrants Price 997,000 $ 1.60 997,000 $ 1.60 775,000 3.00 775,000 3.00 2,388,050 3.35 2,388,050 3.35 72,600 3.80 42,350 3.80 5,000 5.00 5,000 5.00 4,237,650 4,207,400
Schedule of Fair Value of Options Granted by Using Valuation Assumptions	The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows for the options granted during the nine months ended May 31, 2022 and 2021: Schedule of Fair Value of Options Granted by Using Valuation Assumptions 2022 2021 Risk-free interest rate 0.93 1.89 % 0.42 % Expected life of the options 2.5 2.5 Expected volatility 281 % 268 % Expected dividend yield 0 % 0 %	The assumptions used in calculating the fair value of options granted using the Black-Scholes option-pricing model for options granted are as follows: Schedule of Fair Value of Options Granted by Using Valuation Assumptions Years Ended August 31, 2021 2020 Risk-free interest rate 0.42 % 0.21 % Expected life of the options 2.5 2.5 Expected volatility 268 % 281 % Expected dividend yield 0 % 0 %
Schedule of Warrant Activity	The following is a summary of warrant activity: Schedule of Warrant Activity Weighted Weighted Average Average Remaining Aggregate Warrants Exercise Contractual Intrinsic Outstanding Price Life Value Outstanding, August 31, 2021 2,388,050 3.35 5.12 $ - Granted 6,057,214 2.05 Forfeited - Exercised - Outstanding, May 31, 2022 8,445,264 2.42 3.75 $ 291,667 Exercisable, May 31, 2022 8,445,264 $ 2.42 3.75 $ 291,667
Schedule of Warrants Outstanding	The exercise price for warrants outstanding at May 31, 2022: Schedule of Warrants Outstanding Outstanding and Exercisable Number of Exercise Warrants Price 5,833,334 $ 2.00 2,611,930 3.35 8,445,264

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Aug. 31, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective and Statutory Income Tax Rates	A reconciliation of the differences between the effective and statutory income tax rates are as follows: Schedule of Effective and Statutory Income Tax Rates Year Ended August 31, 2021 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (1,102,559 ) $ (3,359,588 ) $ (4,462,147 ) Expected income tax benefit (292,178 ) -26.5 % (907,089 ) -27.0 % (1,199,267 ) Stock based compensation - 0.0 % 278,281 8.3 % 278,281 Change in valuation allowance 292,178 26.5 % 628,808 18.7 % 920,986 $ - 0.0 % $ - 0.0 % $ - 0.0 % Year Ended August 31, 2020 Canada United States Total Combined statutory tax rate 26.5 % 27.0 % Pretax loss $ (232,991 ) $ (4,682,163 ) $ (4,915,154 ) Expected income tax benefit (61,743 ) -26.5 % (1,264,184 ) -27.0 % (1,325,927 ) Stock based compensation - 0.0 % 787,869 16.8 % 787,869 Change in valuation allowance 61,743 26.5 % 476,315 10.2 % 538,058 $ - 0.0 % $ - 0.0 % $ - 0.0 %
Schedule of the Deferred Tax Assets	At August 31, 2021 and 2020, the significant components of the deferred tax asset and liability are summarized below: Schedule of the Deferred Tax Assets 2021 2020 Deferred tax asset: Net operating loss carryforwards $ 4,168,876 $ 2,913,805 Total deferred tax asset 4,168,876 2,913,805 Less: valuation allowance (4,168,876 ) (2,913,805 ) Total deferred tax asset - - Deferred tax liability: Intangible assets (1,500,372 ) - Total deferred tax liability (1,500,372 ) - Net deferred tax liability $ (1,500,372 ) $ -

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended	12 Months Ended
Acquisitions (Tables)	May 31, 2022	Aug. 31, 2021
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 29,291 Inventory 42,273 Prepaid expenses and other current assets 398 Property and equipment 66,759 Intangible assets 1,179,361 Accounts payable and accrued expenses (189,080 ) CEBA loan (47,766 ) Minority interest (97,311 ) Purchase price $ 983,925	A summary of the purchase price allocation for Acenzia and PRO-DIP at fair value is below. Summary of Purchase Price Allocation at Fair Value Acenzia PRO-DIP Cash and cash equivalents $ 3,738,171 $ - Accounts receivable 808,165 - Inventory 195,518 9,050 Prepaid expenses and other current assets 3,594 - Property and equipment 5,687,988 16,355 Intangible assets 6,227,000 455,752 Goodwill 8,726,949 - Accounts payable and accrued expenses (1,845,114 ) - Due to related party (185,614 ) - Note payable (12,534,593 ) (40,320 ) Deferred tax liability (1,536,000 ) - Lease obligation (49,457 ) - Purchase price $ 9,236,607 $ 440,837
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 983,925 $ 983,925	The purchase price was paid as follows: Summary of Purchase Price Acenzia PRO-DIP Cash $ - $ 10,000 Issuance of common stock - 430,837 Common stock to be issued 9,236,607 - $ 9,236,607 $ 440,837
Summary of Unaudited Pro Forma Results of Operations		The following are the unaudited pro forma results of operations for the years ended August 31, 2021 and 2020, as if Acenzia and PRO-DIP had been acquired on September 1, 2019. The pro forma results include estimates and assumptions which management believes are reasonable. However, pro forma results do include any anticipated cost savings or other effects of the planned integration of these entities, and are not necessarily indicative of the results that would have occurred if the business combination had been in effect on the dates indicated. Summary of Unaudited Pro Forma Results of Operations 2021 2020 Pro Forma Combined Financials (unaudited) Years Ended August 31, 2021 2020 Sales $ 12,860,406 $ 14,047,859 Cost of goods sold 8,231,486 8,420,513 Gross profit 4,628,920 5,627,346 Operating expenses 10,285,972 14,091,463 Loss from operations (5,657,052 ) (8,464,117 ) Net loss (6,335,783 ) (9,421,409 ) Loss per share (0.22 ) (0.35 )
Canada Corp [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 7,629 Accounts receivable 2,754 Property and equipment 8,813 Goodwill 31,705 Minority interest (25,401 ) Purchase price $ 25,500
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 25,500 $ 25,500
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 18,383 Accounts receivable 44,289 Prepaid expenses and other current assets 11,292 Property and equipment 9,475 Goodwill 151,686 Purchase price $ 235,125
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock to be issued 235,125 $ 235,125
Clinical Consultants International L L C [Member]
Business Acquisition [Line Items]
Summary of Purchase Price Allocation at Fair Value	Summary of Purchase Price Allocation at Fair Value Cash and cash equivalents $ 2,186 Goodwill 1,701,814 Purchase price $ 1,704,000
Summary of Purchase Price	The purchase price was paid as follows: Summary of Purchase Price Cash $ - Common stock 1,704,000 $ 1,704,000

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended	12 Months Ended
Segment Reporting (Tables)	May 31, 2022	Aug. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following tables summarize the Company’s segment information for the three and nine months ended May 31, 2022 and 2021: Schedule of Segment Reporting Information Healthcare services $ - $ - $ - $ - Three Months Ended May 31, Nine Months Ended May 31, 2022 2021 2022 2021 Sales Healthcare services $ 2,199,889 $ 2,380,974 $ 6,253,089 $ 6,612,374 Product sales 11,651,994 - 13,629,944 - Corporate - - - - $ 13,851,883 $ 2,380,974 $ 19,883,033 $ 6,612,374 Gross profit Healthcare services $ 939,542 $ 1,280,458 $ 2,499,608 $ 2,843,354 Product sales 1,469,340 - 2,392,094 - Corporate - - - - $ 2,408,882 $ 1,280,458 $ 4,891,702 $ 2,843,354 Income (loss) from operations Healthcare services $ (239,981 ) $ 255,129 $ (616,303 ) $ (99,454 ) Product sales 336,348 - (509,342 ) - Corporate (1,299,113 ) (657,101 ) (3,561,436 ) (2,386,186 ) $ (1,202,746 ) $ (401,972 ) $ (4,687,081 ) $ (2,485,640 ) Depreciation and amortization Healthcare services $ 249,831 $ 13,902 $ 393,942 $ 57,840 Product sales 266,166 - 852,692 - Corporate 367,600 367,600 1,102,800 1,061,085 Depreciation and amortization $ 881,597 $ 381,502 $ 2,349,434 $ 1,118,925 Capital expenditures Healthcare services $ - $ 200,751 $ 175,418 $ 201,369 Product sales - - 15,555 - Corporate - - - - Capital expenditures $ - $ 200,751 $ 190,973 $ 201,369 Interest expenses Healthcare services $ 14,532 $ 21,701 $ 54,686 $ 68,590 Product sales 94,765 - 1,067,211 - Corporate 404,101 - 686,413 - Interest expenses $ 513,398 $ 21,701 $ 1,808,310 $ 68,590 Net loss Healthcare services $ (252,122 ) $ 235,867 $ (663,646 ) $ (160,492 ) Product sales (21,153 ) - (2,641,091 ) - Corporate (3,470,750 ) (651,138 ) (7,123,887 ) (2,368,473 ) Net income (loss) $ (3,744,025 ) $ (415,271 ) $ (10,428,624 ) $ (2,528,965 ) Healthcare services $ - $ - As of As of May 31, August 31, 2022 2021 Total assets Healthcare services $ 6,491,538 $ 7,318,888 Product sales 24,830,711 21,427,285 Corporate 40,470,565 33,212,108 Total assets $ 71,792,814 $ 61,958,281 Accounts receivable Healthcare services $ 815,833 $ 953,919 Product sales 1,764,474 514,510 Corporate 2,585,932 - Accounts receivable $ 5,166,239 $ 1,468,429 Intangible assets Healthcare services $ - $ - Product sales 7,224,895 5,958,736 Corporate 24,967,963 26,070,763 Intangible assets $ 32,192,858 $ 32,029,499 Goodwill Healthcare services $ 741,209 $ 557,357 Product sales 8,923,595 8,931,491 Corporate 1,701,814 - Goodwill $ 11,366,618 $ 9,488,848	The following tables summarize the Company’s segment information for the years ended August 31, 2021 and 2020: Schedule of Segment Reporting Information Years Ended August 31, 2021 2020 Sales Healthcare services $ 8,857,693 $ 7,860,567 Product manufacturing and development 447,562 - Corporate - - $ 9,305,255 $ 7,860,567 Gross profit Healthcare services $ 3,694,512 $ 3,058,372 Product manufacturing and development 128,486 - Corporate - - $ 3,822,998 $ 3,058,372 Income (loss) from operations Healthcare services $ (516,437 ) $ 442,656 Product manufacturing and development (580,523 ) - Corporate (3,276,559 ) (4,705,254 ) $ (4,373,519 ) $ (4,262,598 ) Depreciation and amortization Healthcare services $ 91,978 $ 75,726 Product manufacturing and development 203,459 - Corporate 1,428,685 1,369,350 $ 1,724,122 $ 1,445,076 Capital expenditures Healthcare services $ 216,284 $ 12,110 Product manufacturing and development 39,665 - Corporate - - $ 255,949 $ 12,110 Interest expenses Healthcare services $ 89,154 $ 156,662 Product manufacturing and development 75,849 - Corporate - - $ 165,003 $ 156,662 Net loss Healthcare services $ (552,893 ) $ (232,991 ) Product manufacturing and development (656,372 ) - Corporate (3,252,882 ) (4,682,163 ) $ (4,462,147 ) $ (4,915,154 ) As of August 31, 2021 2020 Total assets Healthcare services $ 7,318,888 $ 7,607,820 Product manufacturing and development 21,427,285 - Corporate 33,212,108 27,782,798 $ 61,958,281 $ 35,390,618 Accounts receivable Healthcare services $ 953,919 $ 1,732,432 Product manufacturing and development 514,510 - Corporate - - $ 1,468,429 $ 1,732,432 Intangible assets Healthcare services $ - $ - Product manufacturing and development 6,365,705 - Corporate 26,070,763 26,623,448 $ 32,436,468 $ 26,623,448 Goodwill Healthcare services $ 557,357 $ 636,942 Product manufacturing and development 8,524,522 - Corporate - - $ 9,081,879 $ 636,942

Schedule of Foreign Currency Tr

Schedule of Foreign Currency Translation, Exchange Rate Used (Details)	May 31, 2022	Aug. 31, 2021	May 31, 2021	Aug. 31, 2020
Period End [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7910	0.7917	0.8284	0.7674
Average Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7897	0.7885	0.7834	0.7435

Organization and Basis of Pre_3

Organization and Basis of Presentation (Details Narrative) - USD ($)

3 Months Ended

9 Months Ended

12 Months Ended

May 11, 2022

Oct. 08, 2021

Feb. 01, 2021

Dec. 19, 2019

Dec. 17, 2019

Jan. 30, 2019

Jan. 07, 2019

May 09, 2017

Apr. 25, 2017

May 31, 2022

May 31, 2021

May 31, 2022

Aug. 31, 2021

Aug. 31, 2020

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock issued in connection with reverse merger transaction

$ 1,704,000

$ 430,837

Reverse stock split

the Company effected a 1-for-10 reverse
stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were
exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. At May 31, 2022
and August 31, 2021, there were 30,659,073 and 26,610,144 common shares issued and outstanding, respectively.

Parent Company [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Common stock issued in connection with reverse merger transaction

$ 6,904

Share Exchange Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of restricted shares of common stock, shares

225,000

Joint Venture Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Reverse stock split

The net profits and net losses of the JV will be
split 50/50 between NHL and EK-Tech

Asset Purchase Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of restricted shares of common stock, shares

800,000

Turbine Truck Engines, Inc [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Date of incorporation

Nov. 27, 2000

NHL [Member] | Share Exchange Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of restricted shares of common stock, shares

16,779,741

Percentage of common stock issued and outstanding

85%

Kainai [Member] | Joint Venture Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Number of restricted shares of common stock, shares

1,200,000

Percentage joint venture description

Pursuant to the terms of the Joint Venture Agreement, as assigned to us, the parties
will work in a joint venture relationship (“JV”) with the Company providing the finance, development and operation of the
project, including sales, and Kainai providing the land and approvals for the development of the projects. Pursuant to the terms of the
Joint Venture Agreement, (i) the Company has an 80% controlling interest and Kainai has a 20% interest in the JV; and (ii) the Company
has sole discretion to identify the name and entity under which the JV will operate. The legal entity in which the JV will operate has
not yet been identified or formed. The JV operations will primarily involve the production – including processing, packaging and
sales of natural supplements derived from hemp derived cannabis oils. The joint venture will distribute to the Company and Kainai all
net proceeds after debt and principal servicing and repayment allocation, as well as operating capital allotment, on a ratio equal to
80% to the Company and 20% to Kainai.

Intangible asset, useful life amortized over term

50 years

Number of restricted shares of common stock

$ 21,600,000

Novo Earth Therapeutics Inc [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Controlling interest percentage

70%

Schedule of Estimated Useful Li

Schedule of Estimated Useful Lives of Assets (Details)	9 Months Ended	12 Months Ended
Schedule of Estimated Useful Lives of Assets (Details)	May 31, 2022	Aug. 31, 2021
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	30 years	30 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	3 years	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years	5 years

Schedule of Intangible Assets A

Schedule of Intangible Assets Amortized Estimated Useful Lives (Details)	9 Months Ended	12 Months Ended
	May 31, 2022	Aug. 31, 2021
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	50 years	50 years
Software License [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years	7 years
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years	7 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	5 years	5 years
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years	7 years
Assembled Workforce [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives		5 years

Schedule of Changes in Goodwill

Schedule of Changes in Goodwill (Details) - USD ($)	12 Months Ended
Schedule of Changes in Goodwill (Details) - USD ($)	Aug. 31, 2021	Aug. 31, 2020
Balance, August 31, 2020	$ 636,942
Balance, August 31, 2021	9,488,848	$ 636,942
Previously Reported [Member]
Balance, August 31, 2020	636,942	623,081
Foreign currency translation adjustment	(182,419)	13,861
Goodwill acquired with purchase of business	8,726,949
Impairment of goodwill	(99,593)
Balance, August 31, 2021	9,081,879	636,942
Rockland [Member]
Balance, August 31, 2020	222,546	217,703
Foreign currency translation adjustment	7,047	4,843
Goodwill acquired with purchase of business
Impairment of goodwill
Balance, August 31, 2021	229,593	222,546
Acenzia [Member]
Balance, August 31, 2020
Foreign currency translation adjustment	(202,427)
Goodwill acquired with purchase of business	8,726,949
Impairment of goodwill
Balance, August 31, 2021	8,524,522
APKA [Member]
Balance, August 31, 2020	191,850	187,675
Foreign currency translation adjustment	6,075	4,175
Goodwill acquired with purchase of business
Impairment of goodwill
Balance, August 31, 2021	197,925	191,850
EFL [Member]
Balance, August 31, 2020	222,546	217,703
Foreign currency translation adjustment	6,886	4,843
Goodwill acquired with purchase of business
Impairment of goodwill	(99,593)
Balance, August 31, 2021	$ 129,839	$ 222,546

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)				3 Months Ended	9 Months Ended		12 Months Ended
	May 31, 2022	Nov. 17, 2021	Jul. 21, 2020	May 31, 2022	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020	Mar. 02, 2022	Dec. 14, 2021
Product Information [Line Items]
Allowance for uncollectible accounts receivable	$ 705,384			$ 705,384	$ 705,384		$ 1,097,628	$ 518,031
Inventory	$ 1,065,777			$ 1,065,777	$ 1,065,777		1,066,721
Other receivable written off							$ 0	29,744
Contract lease term	12 months			12 months	12 months		12 months
Impairment charges on goodwill							$ 99,593
Acquisition deposits								$ 383,700
Debt rate		1%						10%		5%
Debt due date		May 17, 2022					Sep. 01, 2022
Other comprehensive income	$ 1,015,993			$ 1,015,993	$ 1,015,993		$ 991,077	$ 1,199,696
Debt conversion, converted instrument, shares issued			15,091		8,270,812	4,308,591
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Product Information [Line Items]
Concentration risk percentage	40%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage				70%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage					50%
Share-Based Payment Arrangement, Option [Member]
Product Information [Line Items]
Potentially dilutive common stock options and warrants outstanding, shares					10,624,849	1,849,600	4,237,650	1,784,500
Novo Healthnet Kemptville Centre, Inc [Member]
Product Information [Line Items]
Equity method investment, ownership percentage	80%			80%	80%		80%
Novo Earth Therapeutics Inc [Member]
Product Information [Line Items]
Equity method investment, ownership percentage	70%			70%	70%		70%
Terrengenx [Member]
Product Information [Line Items]
Equity method investment, ownership percentage	91%			91%	91%
Canada Corp [Member]
Product Information [Line Items]
Equity method investment, ownership percentage	50.10%			50.10%	50.10%				50.10%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)			9 Months Ended
Related Party Transactions (Details Narrative) - USD ($)	Jul. 21, 2020	Jul. 21, 2020	May 31, 2022	May 31, 2021	Dec. 14, 2021	Nov. 17, 2021	Aug. 31, 2021	Dec. 11, 2020	Aug. 31, 2020
Related Party Transaction [Line Items]
Due to related parties			$ 456,528				$ 478,920		$ 528,213
Monthly lease payments			$ 2,827,890				3,258,942
Related party debt, converted amount	$ 226,363
Debt converted, shares issued	15,091		8,270,812	4,308,591
Debt conversion price	$ 15	$ 15						$ 3.65
Proceeds from (Repayments of) Related Party Debt		$ 267,768
Secured Debt			$ 981,337				982,205		$ 952,058
Debt instrument, interest rate, percentage					5%	1%			10%
Related Party [Member]
Related Party Transaction [Line Items]
Monthly lease payments							1,487
Non-Interest Bearing [Member]
Related Party Transaction [Line Items]
Due to related parties			384,723				407,052		$ 458,550
6% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties			$ 22,763				$ 22,783		22,084
Debt instrument, interest rate, percentage			6%				6%
13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties			$ 49,042				$ 49,085		$ 47,579
Debt instrument, interest rate, percentage			13.75%				13.75%

Schedule of Inventory (Details)

Schedule of Inventory (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,162,067	$ 1,017,566
Work in process	144,500	144,628
Finished Goods	404,273	243,912
Inventory, Gross	1,710,840	1,406,106
Allowance for slow moving and obsolete inventory	(1,065,777)	(1,066,721)
Inventory, net	645,063	339,385
Inventory Gross	1,710,840	1,406,106
Inventory, net	$ 645,063	$ 339,385

Schedule of Accounts Receivable

Schedule of Accounts Receivables, Net (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Receivables [Abstract]
Trade receivables	$ 5,739,193	$ 2,411,499	$ 1,948,520
Amounts earned but not billed	132,430	154,558	301,943
Accounts receivable gross	5,871,623	2,566,057	2,250,463
Allowance for doubtful accounts	(705,384)	(1,097,628)	(518,031)
Accounts receivable, net	$ 5,166,239	$ 1,468,429	$ 1,732,432

Schedule of Other Receivables (

Schedule of Other Receivables (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 1,209,137	$ 1,506,895	$ 590,439
Current portion	(1,209,137)	(814,157)	(302,664)
Long-term portion		692,738	287,775
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables		296,888	287,775
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	79,100	79,170	76,740
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	225,924	225,924	225,924
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	508,613	509,063
Advance to Corporation Four [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 395,500	$ 395,850

Schedule of Other Receivables_2

Schedule of Other Receivables (Details) (Parenthetical)	9 Months Ended	12 Months Ended
Schedule of Other Receivables (Details) (Parenthetical)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Notes Receivable Dated April 1, 2015 and May 23, 2017 [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	8%	8%	8%
Notes receivable due date	Mar. 01, 2019	Mar. 01, 2019	Mar. 01, 2019
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%	12%
Notes receivable due date	Jan. 31, 2023	Jan. 31, 2023	Dec. 31, 2021
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10%	10%	10%
Notes receivable due date	May 01, 2023	May 01, 2023	Mar. 01, 2022
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12%	12%	12%
Notes receivable due date	Aug. 01, 2022	Aug. 01, 2022	Feb. 01, 2022
Advance to Corporation Four [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10%	10%	10%
Notes receivable due date	Sep. 01, 2022	Sep. 01, 2022	Sep. 01, 2022

Other Receivables (Details Narr

Other Receivables (Details Narrative)	Aug. 31, 2020 USD ($)
Receivables [Abstract]
Other receivable loss on settlement	$ 74,360
Note receivable written off	$ 29,744

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 6,986,811	$ 6,716,733	$ 860,104
Accumulated depreciation	(1,055,128)	(646,442)	(506,444)
Total	5,931,683	6,070,291	353,660
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	474,600	475,020
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	3,559,500	3,562,650
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	861,188	691,318	465,857
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	1,973,582	1,875,537	301,337
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	27,116	24,679	23,921
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	49,842	46,510	29,229
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment gross	$ 40,983	$ 41,019	$ 39,760

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
Property and Equipment (Details Narrative) - USD ($)	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 408,589	$ 57,840	$ 123,461	$ 75,726

Schedule of Intangible Assets (

Schedule of Intangible Assets (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 37,091,484	$ 34,986,108	$ 27,992,798
Accumulated amortization	(4,898,626)	(2,956,609)	(1,369,350)
Total	32,192,858	32,029,499	26,623,448
Previously Reported [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		35,407,111
Accumulated amortization		(2,970,643)
Total		32,436,468
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	21,600,000	21,600,000	21,600,000
Software License [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	1,144,798	1,144,798	1,144,798
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	11,495,963	9,388,065	5,248,000
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	786,608	787,304
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 2,064,115	2,065,941
Assembled Workforce [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross		$ 421,003

Schedule of Expected Amortizati

Schedule of Expected Amortization Expense of Intangible Assets (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
2023	$ 2,690,018	$ 2,473,490
2024	2,690,018	2,473,490
2025	2,690,018	2,473,490
2026	2,662,926	2,473,490
2027	2,115,863	2,379,029
Thereafter	19,344,015	20,163,479
Total	$ 32,192,858	32,029,499	$ 26,623,448
Previously Reported [Member]
Total		$ 32,436,468

Schedule of Software Deliverabl

Schedule of Software Deliverables and Payments (Details) - Feb. 26, 2019 - Software License Agreement [Member] - Cloud DX, Inc. [Member]	USD ($)	CAD ($)
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	$ 189,642	$ 250,000
Heart Friendly Program Launches in Clinic [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	37,929	50,000
Novo-Branded Android App [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	26,550	35,000
Novo-Branded Clinical Portal Website [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	26,550	35,000
Pulsewave PAD-1A Devices [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	15,171	20,000
Marketing Services / Materials Delivered [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	18,964	25,000
Novo Support FTE [Member]
Finite-Lived Intangible Assets [Line Items]
Payments to acquire software license	$ 64,478	$ 85,000

Intangible Assets (Details Narr

Intangible Assets (Details Narrative)					1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended
Intangible Assets (Details Narrative)	Mar. 06, 2020 USD ($) shares	Mar. 06, 2020 CAD ($) shares	Feb. 26, 2019 USD ($) shares	Feb. 26, 2019 CAD ($) shares	Dec. 17, 2019 USD ($) shares	Nov. 30, 2021 USD ($)	May 31, 2022 USD ($)	May 31, 2021 USD ($)	Aug. 31, 2021 USD ($)	Aug. 31, 2020 USD ($) shares	Mar. 06, 2021 USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization of intangible assets							$ 1,940,845	$ 1,061,085	$ 1,600,661	$ 1,369,350
Shares issued during period for intellectual property						$ 188,925			$ 876,000
Intellectual Property Asset Purchase Agreement [Member]
Finite-Lived Intangible Assets [Line Items]
Shares issued during period for intellectual property, shares \| shares					800,000					800,000
Shares issued during period for intellectual property					$ 5,248,000					$ 5,248,000
Software License Agreement [Member] \| Cloud DX, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock \| shares			45,835	45,835
Number of restricted shares of common stock, value			$ 758,567	$ 1,000,000
Payments to acquire software license			$ 189,642	$ 250,000
Perpetual Software License Agreement [Member] \| Cloud DX, Inc. [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock \| shares	46,558	46,558
Payments to acquire software license	$ 186,231	$ 250,000
Cloud DX Amendment [Member] \| Novo Healthnet Limited, Inc [Member]
Finite-Lived Intangible Assets [Line Items]
Number of restricted shares of common stock \| shares	50,000	50,000
Payments to acquire software license	$ 200,000
Cloud DX Amendment [Member] \| Pro-Dip, LLC [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquisition, intangible assets											$ 455,752
Cloud DX Amendment [Member] \| Acenzia Inc [Member] \| Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquisition, intangible assets											2,875,000
Cloud DX Amendment [Member] \| Acenzia Inc [Member] \| Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquisition, intangible assets											806,000
Cloud DX Amendment [Member] \| Acenzia Inc [Member] \| Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquisition, intangible assets											2,115,000
Cloud DX Amendment [Member] \| Acenzia Inc [Member] \| Assembled Workforce [Member]
Finite-Lived Intangible Assets [Line Items]
Business acquisition, intangible assets											$ 431,000

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Payables and Accruals [Abstract]
Accrued liabilities	$ 1,023,005	$ 811,660	$ 37,457
Accrued payroll	182,231	279,018	117,823
Unearned revenue	38,556	38,631	39,428
Accrued expenses	$ 1,243,792	$ 1,129,309	$ 194,708

Schedule of Governmental Loans

Schedule of Governmental Loans and Note Payable (Details) - USD ($)		9 Months Ended		12 Months Ended
	Nov. 17, 2021	May 31, 2022		Aug. 31, 2021		Aug. 31, 2020
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 5,418,701		$ 9,619,253		$ 83,292
Debt instrument, maturity date	May 17, 2022			Sep. 01, 2022
Less current portion		(5,260,056)		$ (4,485,649)		(83,292)
Long-term portion		158,645		5,133,604
Notes Payable [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable						21,900
Notes Payable One [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		94,920	[1]	63,336	[1]	61,392
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		40,320		40,320
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 5,252,749		$ 5,069,858
Debt instrument, maturity date		Jun. 30, 2022		Jun. 30, 2022
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable		$ 30,712		$ 30,739
Debt instrument, maturity date		Dec. 31, 2028		Dec. 31, 2028		Dec. 02, 2028
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Total government loans and notes payable				$ 4,415,000
Debt instrument, maturity date		Jun. 24, 2022		Jun. 24, 2022

[1]The Government of Canada launched CEBA loan to ensure that small businesses have access to the capital that they need during the current challenges faced due to the COVID-19 virus. The Company obtained CAD$ 80,000 63,280 If the loan amount is paid on or before December 31, 2023, 25 75 60,000 20,000 31,640

Schedule of Governmental Loan_2

Schedule of Governmental Loans and Note Payable (Details) (Parenthetical)		9 Months Ended		12 Months Ended
	Nov. 17, 2021	May 31, 2022 USD ($)	May 31, 2022 CAD ($)	Aug. 31, 2021 USD ($)	Aug. 31, 2020	May 31, 2022 CAD ($)	Aug. 31, 2021 CAD ($)
Short-Term Debt [Line Items]
Debt Instrument, Maturity Date	May 17, 2022			Sep. 01, 2022
Interest rate during period not repay		75%	75%
Notes Payable [Member]
Short-Term Debt [Line Items]
Debt instrument, term				24 months
Debt Instrument, Interest Rate During Period				1%
Notes Payable Two [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period		3.75%	3.75%	3.75%
Frequency of periodic payment		monthly	monthly	monthly
Periodic payment		$ 190		$ 190
Notes Payable Three [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period		3%	3%	3%
Debt Instrument, Maturity Date		Jun. 30, 2022	Jun. 30, 2022	Jun. 30, 2022
Notes Payable Four [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period		4.53%	4.53%	4.53%
Frequency of periodic payment		annual	annual	annual
Periodic payment		$ 4,000		$ 4,000
Debt Instrument, Maturity Date		Dec. 31, 2028	Dec. 31, 2028	Dec. 31, 2028	Dec. 02, 2028
Notes Payable Five [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period		9%	9%	9%
Debt Instrument, Maturity Date		Jun. 24, 2022	Jun. 24, 2022	Jun. 24, 2022
Periodic payment principal		$ 950,000		$ 950,000
Canada Emergency Business Account Loan [Member]
Short-Term Debt [Line Items]
Debt Instrument, Interest Rate During Period		25%	25%	25%
Debt Instrument, Maturity Date				Dec. 31, 2022
Notes Payable		$ 63,280		$ 63,336		$ 80,000	$ 80,000
Debt Instrument, Description		If the loan amount is paid on or before December 31, 2023, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2023, the Early Payment Credit will not apply. In addition, with acquisition of Terragenx, the Company acquired a CEBA loan in the amount of CAD$60,000 net of CAD$20,000 repayment (US$31,640 at May 31, 2022) under the same terms.	If the loan amount is paid on or before December 31, 2023, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2023, the Early Payment Credit will not apply. In addition, with acquisition of Terragenx, the Company acquired a CEBA loan in the amount of CAD$60,000 net of CAD$20,000 repayment (US$31,640 at May 31, 2022) under the same terms.	If the loan amount is paid on or before December 31, 2022, 25% of the loan will be forgiven (“Early Payment Credit”). In the event that the Company does not repay 75% of such term debt on or before December 31, 2022, the Early Payment Credit will not apply
Canada Emergency Business Account Loan [Member] \| Terragenx [Member]
Short-Term Debt [Line Items]
Notes Payable		$ 31,640				$ 60,000
Repayment of debt			$ 20,000

Schedule of Future Maturities O

Schedule of Future Maturities Outstanding of Governmental Loans and Note Payable (Details) - USD ($)	May 31, 2022	Aug. 31, 2021
Government Loans And Note Payable And Government Subsidy
2023	$ 5,260,056	$ 4,485,649
2024	99,822	5,074,763
2025	5,343	5,346
2026	5,790	5,793
2027	6,244	6,247
Thereafter	41,446	41,455
Total	$ 5,418,701	$ 9,619,253

Government Loans and Note Pay_3

Government Loans and Note Payable and Government Subsidy (Details Narrative) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2022	Aug. 31, 2021
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate during period not repay	75%
C E W S [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Interest rate during period not repay	75%
Canada Emergency Wage Subsidy [Member] \| General and Administrative Expense [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Government subsidies	$ 731,000	$ 731,000

Debentures, Related Parties (De

Debentures, Related Parties (Details Narrative)

9 Months Ended

12 Months Ended

Nov. 17, 2021

Nov. 02, 2021

Jul. 21, 2020 $ / shares shares

Jul. 21, 2020 USD ($) $ / shares

Sep. 27, 2019

Jan. 31, 2018 USD ($) $ / shares shares

Dec. 02, 2017

Sep. 30, 2013 USD ($)

May 31, 2022 USD ($) shares

May 31, 2021 shares

Aug. 31, 2021 USD ($)

Dec. 14, 2021

Dec. 11, 2020 $ / shares

Aug. 31, 2020 USD ($)

Sep. 30, 2013 CAD ($)

Short-Term Debt [Line Items]

Debentures, outstanding

$ 981,337

$ 982,205

$ 952,058

Debt interest rate

10%

Debt due date

May 17, 2022

Sep. 01, 2022

Debt converted, shares issued | shares

15,091

8,270,812

4,308,591

Debt conversion price | $ / shares

$ 15

$ 3.65

Repayment of related party debt

$ 267,768

Five Debentures [Member]

Short-Term Debt [Line Items]

Debentures, outstanding

$ 6,225,163

$ 6,402,512

Debt interest rate

Debt due date

Dec. 01, 2023

Sep. 30, 2021

Sep. 30, 2019

Sep. 30, 2016

Five Debentures [Member] | Forecast [Member]

Short-Term Debt [Line Items]

Debt due date

Dec. 01, 2023

Debentures [Member]

Short-Term Debt [Line Items]

Debentures, outstanding

$ 3,894,809

Percentage of debt converted

75%

Accrued interest

$ 414,965

Debt converted, shares issued | shares

1,047,588

Debt conversion, description

The per share price used for the conversion of each debenture was $4.11 which was determined as the average price of the five (5) trading days immediately preceding the date of conversion with a 10% premium added to the calculated per share price.

Debt conversion price | $ / shares

$ 4.11

Schedule of Lease Related Asset

Schedule of Lease Related Assets and Liabilities (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Leases
Operating lease assets	$ 2,222,970	$ 2,543,396	$ 2,810,556
Total lease assets	2,222,970	2,543,396	2,810,556
Current liabilities- Operating lease liability	544,690	530,797	563,793
Noncurrent liabilities - Operating lease liability	1,734,790	2,057,805	2,266,887
Total lease liability	$ 2,279,480	$ 2,588,602	$ 2,830,680

Schedule of Lease Obligations (

Schedule of Lease Obligations (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Leases
2023	$ 707,309	$ 717,772
2024	491,435	649,974
2025	406,221	444,301
2026	379,585	366,620
2027	378,902	351,434
Thereafter	464,438	728,841
Total payments	2,827,890	3,258,942
Amount representing interest	(548,410)	(670,340)
Lease obligation, net	2,279,480	2,588,602	$ 2,830,680
Less lease obligation, current portion	(544,690)	(530,797)	(563,793)
Lease obligation, long-term portion	$ 1,734,790	$ 2,057,805	$ 2,266,887

Schedule of Finance Leases (Det

Schedule of Finance Leases (Details) - USD ($)	May 31, 2022	Aug. 31, 2021
Leases
Cost	$ 209,457	$ 209,457
Accumulated amortization	(178,383)	(136,491)
Net book value	$ 31,074	$ 72,966

Schedule of Future Minimum Leas

Schedule of Future Minimum Lease Payments (Details) - USD ($)	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Leases
2023	$ 16,631	$ 25,153
2024	8,092	9,719
2024		5,669
Total payments	24,723	40,541
Amount representing interest	(178)	(1,140)
Lease obligation, net	24,545	39,401
Less lease obligation, current portion	(15,982)	(23,184)
Lease obligation, long-term portion	$ 8,563	$ 16,217

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	9 Months Ended		12 Months Ended
Leases (Details Narrative) - USD ($)	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020
Lease obligation	$ 418,188	$ 467,864	$ 642,991	$ 541,530
Lease expense	567,772	629,029	858,847	788,272
Cash paid under operating leases	$ 556,445	$ 621,228	$ 834,502	$ 772,798
Weighted average remaning lease term	5 years 6 months 18 days		5 years 11 months 23 days
Weighted average discount rate	8%		8%
Lease payments implicit borrowing rate	5%
New Lease [Member]
Lease obligation	$ 100,711		$ 296,317

Schedule of Stock Option and Wa

Schedule of Stock Option and Warrant Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options/Warrants outstanding, beginning balance	1,849,600
Weighted average exercise price, outstanding, beginning balance	$ 2.29
Weighted average remaining contractual life, outstanding, beginning balance	3 years 1 month 20 days
Aggregate intrinsic value, outstanding, beginning balance	$ 218,240
Options/Warrants outstanding, granted	329,985
Weighted average exercise price, granted	$ 1.41
Options/Warrants outstanding, forfeited
Options/Warrants Outstanding, Exercised		(7,500)
Options/Warrants outstanding, ending balance	2,179,585	1,849,600
Weighted average exercise price, outstanding, ending balance	$ 2.16	$ 2.29
Weighted average remaining contractual life, outstanding, ending balance	2 years 8 months 26 days
Aggregate intrinsic value, outstanding, ending balance	$ 658,069	$ 218,240
Options/Warrants outstanding, exercisable	1,968,096
Weighted average exercise price, exercisable	$ 2.25
Weighted average remaining contractual life, exercisable	2 years 6 months 7 days
Aggregate intrinsic value, outstanding, ending balance	$ 505,797
Options/Warrants outstanding, exercised		7,500
Stock Option and Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Options/Warrants outstanding, beginning balance	4,237,650	1,784,500	1,009,500
Weighted average exercise price, outstanding, beginning balance	$ 2.89	$ 2.20	$ 3
Weighted average remaining contractual life, outstanding, beginning balance		4 years 1 month 2 days	3 years 6 months 29 days
Aggregate intrinsic value, outstanding, beginning balance	$ 218,240	$ 3,173,800	$ 1,141,500
Options/Warrants outstanding, granted		2,460,650	775,000
Weighted average exercise price, granted		$ 3.36	$ 3
Options/Warrants outstanding, forfeited
Options/Warrants Outstanding, Exercised		(7,500)
Weighted Average Exercise Price, Exercised		$ 1.60
Options/Warrants outstanding, ending balance		4,237,650	1,784,500
Weighted average exercise price, outstanding, ending balance		$ 2.89	$ 2.20
Weighted average remaining contractual life, outstanding, ending balance		4 years 3 months 3 days
Aggregate intrinsic value, outstanding, ending balance		$ 218,240	$ 3,173,800
Options/Warrants outstanding, exercisable		4,207,400
Weighted average exercise price, exercisable		$ 2.88
Weighted average remaining contractual life, exercisable		4 years 3 months
Aggregate intrinsic value, outstanding, ending balance		$ 218,240
Options/Warrants outstanding, exercised		7,500

Schedule of Options and Warrant

Schedule of Options and Warrants Outstanding and Exercisable (Details) - $ / shares	May 31, 2022	Aug. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding	2,179,585	1,849,600
Number of options/warrants, exercisable	1,968,096
Stock Option And Warrant Membe [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Options/Warrants, Outstanding		4,237,650
Number of Options/Warrants, Exercisable		4,207,400
Exercise Price Range One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding, exercise price	$ 1.33
Number of options/warrants, exercisable, exercise price	$ 1.33
Number of options/warrants, outstanding	281,985
Number of options/warrants, exercisable	70,496
Exercise Price Range One [Member] \| Stock Option And Warrant Membe [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Options/Warrants, Outstanding		997,000
Number of options/warrants, outstanding, exercise price		$ 1.60
Number of Options/Warrants, Exercisable		997,000
Number of options/warrants, exercisable, exercise price		$ 1.60
Exercise Price Range Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding, exercise price	$ 1.60
Number of options/warrants, exercisable, exercise price	$ 1.60
Number of options/warrants, outstanding	997,000
Number of options/warrants, exercisable	997,000
Exercise Price Range Two [Member] \| Stock Option And Warrant Membe [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Options/Warrants, Outstanding		775,000
Number of options/warrants, outstanding, exercise price		$ 3
Number of Options/Warrants, Exercisable		775,000
Number of options/warrants, exercisable, exercise price		$ 3
Exercise Price Range Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding, exercise price	$ 1.87
Number of options/warrants, exercisable, exercise price	$ 1.87
Number of options/warrants, outstanding	48,000
Number of options/warrants, exercisable	48,000
Exercise Price Range Three [Member] \| Stock Option And Warrant Membe [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Options/Warrants, Outstanding		2,388,050
Number of options/warrants, outstanding, exercise price		$ 3.35
Number of Options/Warrants, Exercisable		2,388,050
Number of options/warrants, exercisable, exercise price		$ 3.35
Exercise Price Range Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding, exercise price	$ 3
Number of options/warrants, exercisable, exercise price	$ 3
Number of options/warrants, outstanding	775,000
Number of options/warrants, exercisable	775,000
Exercise Price Range Four [Member] \| Stock Option And Warrant Membe [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Options/Warrants, Outstanding		72,600
Number of options/warrants, outstanding, exercise price		$ 3.80
Number of Options/Warrants, Exercisable		42,350
Number of options/warrants, exercisable, exercise price		$ 3.80
Exercise Price Range Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding, exercise price	$ 3.80
Number of options/warrants, exercisable, exercise price	$ 3.80
Number of options/warrants, outstanding	72,600
Number of options/warrants, exercisable	72,600
Exercise Price Range Five [Member] \| Stock Option And Warrant Membe [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Options/Warrants, Outstanding		5,000
Number of options/warrants, outstanding, exercise price		$ 5
Number of Options/Warrants, Exercisable		5,000
Number of options/warrants, exercisable, exercise price		$ 5
Exercise Price Range Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options/warrants, outstanding, exercise price	$ 5
Number of options/warrants, exercisable, exercise price	$ 5
Number of options/warrants, outstanding	5,000
Number of options/warrants, exercisable	5,000

Schedule of Fair Value of Optio

Schedule of Fair Value of Options Granted by Using Valuation Assumptions (Details)	9 Months Ended		12 Months Ended
	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020
Risk-free interest rate		0.42%	0.42%	0.21%
Expected life of the options	2 years 6 months	2 years 6 months	2 years 6 months	2 years 6 months
Expected volatility	281%	268%	268%	281%
Expected dividend yield	0%	0%	0%	0%
Minimum [Member]
Risk-free interest rate	0.93%
Maximum [Member]
Risk-free interest rate	1.89%

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative)													1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
Stockholders’ Equity (Details Narrative)	May 11, 2022 shares	May 02, 2022 USD ($) shares	Apr. 07, 2022 USD ($) shares	Mar. 18, 2022 USD ($) shares	Feb. 24, 2022 USD ($) shares	Jan. 24, 2022 USD ($) shares	Dec. 20, 2021 USD ($) shares	May 24, 2021 USD ($) $ / shares shares	Apr. 13, 2021 USD ($) $ / shares shares	Feb. 01, 2021	Jul. 21, 2020 USD ($)	Dec. 17, 2019 shares	Dec. 17, 2019 USD ($) shares	May 31, 2022 USD ($) $ / shares shares	Nov. 30, 2021 USD ($)	May 31, 2021 USD ($) $ / shares	Nov. 30, 2020 USD ($)	May 31, 2022 USD ($) $ / shares shares	May 31, 2021 USD ($) $ / shares	Aug. 31, 2021 USD ($) $ / shares shares	Aug. 31, 2020 USD ($) $ / shares shares	Aug. 31, 2020 CAD ($) shares	Nov. 17, 2021 USD ($) $ / shares	Feb. 09, 2021 shares	Jan. 16, 2018 shares	Sep. 08, 2015 shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Convertible preferred stock, shares authorized														1,000,000				1,000,000		1,000,000	1,000,000
Convertible preferred stock, par value \| $ / shares														$ 0.001				$ 0.001		$ 0.001	$ 0.001
Convertible preferred stock, shares issued														0				0		0	0
Convertible preferred stock, shares outstanding														0				0		0	0
Common stock, shares authorized														499,000,000				499,000,000		499,000,000	499,000,000
Common stock, par value \| $ / shares														$ 0.001				$ 0.001		$ 0.001	$ 0.001
Reverse stock split										the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share.								the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share. At May 31, 2022 and August 31, 2021, there were 30,659,073 and 26,610,144 common shares issued and outstanding, respectively.		the Company effected a 1-for-10 reverse stock split of our common stock. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share
Common stock, shares issued														30,659,073				30,659,073		26,610,144	23,466,236
Common stock, shares outstanding														30,659,073				30,659,073		26,610,144	23,466,236
Shares issued during period for intellectual property \| $															$ 188,925					$ 876,000
Closing price per share \| $ / shares																							$ 3.35
Stock issued during period, shares, reverse stock splits																				957
Stock issued during period, stock options exercised																				7,500
Stock issued during period, value, stock options exercised \| $																				$ 12,000
Issuance of common stock \| $																$ 7,235,580	$ 92,000			$ 7,327,580	$ 113,399
Weighted average fair value \| $ / shares																		$ 1.37	$ 3.76	$ 3.76	$ 2.92
Weighted-average exercise price \| $ / shares																				$ 3.80	$ 3
Stock option expense \| $																		$ 289,892	$ 88,855	$ 155,496	$ 2,265,211
Unamortized stock option expense \| $														$ 273,991				$ 273,991		$ 111,068
Number of options granted														2,179,585				2,179,585		1,849,600
Expense associated with modified stock option terms \| $																					$ 62,822
Debt instrument, face amount \| $														$ 16,666,666				$ 16,666,666					$ 1,875,000
Weighted-average exercise price \| $ / shares														$ 1.41		$ 3.80		$ 1.41	$ 3.80
Convertible Debt [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares														623,929
Debt instrument aggregate principal amount \| $														$ 1,244,444				$ 1,244,444
Accrued interest \| $														$ 3,405				$ 3,405
Option 1 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options granted																					449,500
Exercise price, re-priced \| $ / shares																					$ 1.60
Option 2 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of options granted																					437,000
Acenzia Inc [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Shares issued for acquisition, shares																				3,622,199
Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																					35,437	35,437
Issuance of common stock \| $																					$ 113,399
2021 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock shares authorized																								4,500,000
Number of shares available for future grant														4,039,315				4,039,315		4,369,300
Term of award description																		the maximum aggregate number of shares that may be issued under the 2021 Plan is eligible to be cumulatively increased on January 1, 2022 and on each subsequent January 1 through and including January 1, 2023, by a number of shares equal to the smaller of (i) 3% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or (ii) an amount determined by our Board of Directors. The Company chose not to cumulatively increase the shares authorized for issuance under the 2021 Plan effective January 1, 2022. As of May 31, 2022, the 2021 Plan had 4,039,315 shares available for award.
2015 Incentive Compensation Plan [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock shares authorized																										500,000
2018 Incentiven Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of common stock shares authorized																									1,000,000
Number of shares available for future grant														864,900				864,900		864,900
Consulting and Services Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares																		35,000		50,000
Proceeds from issuance of restricted shares \| $																		$ 64,750		$ 192,500
Shares issuance date																		Sep. 16, 2021
Asset Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares												800,000
Number of restricted shares																				240,000
Shares issued during period for intellectual property \| $																				$ 876,000
Closing price per share \| $ / shares																				$ 3.65
Letter of Engagement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares																				100,000
Proceeds from issuance of restricted shares \| $																				$ 375,000
Legal Services [Member] \| 2021 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																				9,913
Issuance of common stock \| $																				$ 37,172
Share Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares								189,796
Proceeds from issuance of restricted shares \| $								$ 430,837
Closing price per share \| $ / shares								$ 2.27
Shares Issued for Medical Services [Member] \| 2021 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																				120,787
Issuance of common stock \| $																				$ 215,000
Intellectual Property Asset Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares													800,000								800,000	800,000
Shares issued during period for intellectual property \| $													$ 5,248,000								$ 5,248,000
Closing price per share \| $ / shares																					$ 6.56
License Agreement Amendment [Member] \| Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Closing price per share \| $ / shares																					$ 4
Number of shares issued																					96,558	96,558
Issuance of common stock \| $																					$ 386,231
Related Party Loan Debt [Member] \| Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Closing price per share \| $ / shares																					$ 15
Number of shares issued																					15,091	15,091
Issuance of common stock											$ 226,363											$ 304,321
Services [Member] \| Restricted Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																					100,000	100,000
Issuance of common stock \| $																					$ 340,000
Shares Issued for Consulting Services [Member] \| 2021 Equity Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of shares issued																					50,000	50,000
Issuance of common stock \| $																					$ 250,000
Escrow Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares																		2,000,000
Shares issuance date																		Nov. 17, 2021
Shares held in escrow, value \| $														$ 0				$ 0
Escrow Agreement [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Debt instrument, face amount \| $														$ 1,875,000				$ 1,875,000
Consulting Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares		50,000			50,000		50,000
Proceeds from issuance of restricted shares \| $		$ 107,000			$ 64,500		$ 65,500
Shares issuance date		May 02, 2022			Feb. 24, 2022		Dec. 20, 2021
Contractor Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares				50,000
Proceeds from issuance of restricted shares \| $				$ 138,000
Number of restricted shares						25,000
Shares issued during period for intellectual property \| $						$ 30,000
Shares issuance date				Mar. 18, 2022		Jan. 24, 2022
Contractor Agreement One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares				25,000
Proceeds from issuance of restricted shares \| $				$ 69,000
Number of restricted shares						65,000
Shares issued during period for intellectual property \| $						$ 78,000
Shares issuance date				Mar. 18, 2022		Jan. 24, 2022
Consulting Agreement One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares						50,000
Proceeds from issuance of restricted shares \| $						$ 60,000
Shares issuance date						Jan. 24, 2022
Membership Interest Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares			800,000
Proceeds from issuance of restricted shares \| $			$ 1,704,000
Shares issuance date			Apr. 07, 2022
Share Exchange Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares	225,000
Shares issuance date	May 11, 2022
Non-U.S. Person [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares																				21,905
Proceeds from issuance of restricted shares \| $																				$ 92,000
Independent Contractor [Member] \| Statement of Work Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of restricted shares																				15,000
Proceeds from issuance of restricted shares \| $																				$ 55,500
Accredited Investors [Member] \| Asset Purchase Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Closing price per share \| $ / shares									$ 3.35
Number of shares issued									2,388,050
Offering cost, incurred \| $									$ 764,388

Schedule of Effective and Statu

Schedule of Effective and Statutory Income Tax Rates (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	May 31, 2022	May 31, 2021	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020
Pretax income (loss)					$ (4,462,147)	$ (4,915,154)
Expected income tax expense (benefit)					(1,199,267)	(1,325,927)
Stock based compensation					278,281	787,869
Change in valuation allowance					920,986	538,058
Total
Total percentage					0%	0%
CANADA
Combined statutory tax rate					26.50%	26.50%
Pretax income (loss)					$ (1,102,559)	$ (232,991)
Expected income tax expense (benefit)					$ (292,178)	$ (61,743)
Expected income tax expense (benefit), percentage					(26.50%)	(26.50%)
Stock based compensation
Stock based compensation, percentage					0%	0%
Change in valuation allowance					$ 292,178	$ 61,743
Change in valuation allowance, percentage					26.50%	26.50%
Total
Total percentage					0%	0%
UNITED STATES
Combined statutory tax rate					27%	27%
Pretax income (loss)					$ (3,359,588)	$ (4,682,163)
Expected income tax expense (benefit)					$ (907,089)	$ (1,264,184)
Expected income tax expense (benefit), percentage					(27.00%)	(27.00%)
Stock based compensation					$ 278,281	$ 787,869
Stock based compensation, percentage					8.30%	16.80%
Change in valuation allowance					$ 628,808	$ 476,315
Change in valuation allowance, percentage					18.70%	10.20%
Total
Total percentage					0%	0%

Schedule of the Deferred Tax As

Schedule of the Deferred Tax Assets (Details) - USD ($)	Aug. 31, 2021	Aug. 31, 2020
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 4,168,876	$ 2,913,805
Total deferred income tax asset	4,168,876	2,913,805
Less: valuation allowance	(4,168,876)	(2,913,805)
Total deferred income tax asset
Amortization of intangible assets	(1,500,372)
Total deferred tax liability	(1,500,372)
Net deferred tax liability	$ (1,500,372)

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
Income Taxes (Details Narrative) - USD ($)	Aug. 31, 2021	Aug. 31, 2020
Increases in valuation allowances	$ 1,255,071	$ 787,060
Deferred tax valuation allowances	4,168,876	2,913,805
Operating loss carry forward	4,168,876	$ 2,913,805
UNITED STATES
Operating loss carry forward	5,577,000
CANADA
Operating loss carry forward	$ 5,643,000

Summary of Purchase Price Alloc

Summary of Purchase Price Allocation at Fair Value (Details) - USD ($)	9 Months Ended	12 Months Ended
	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Business Acquisition [Line Items]
Cash and cash equivalents	$ 29,291
Inventory	42,273
Prepaid expenses and other current assets	398
Property and equipment	66,759
Intangible assets	1,179,361
Goodwill	11,366,618	$ 9,488,848	$ 636,942
Accounts payable and accrued expenses	(189,080)
Purchase price	983,925
CEBA loan	(47,766)
Minority interest	(97,311)
Canada Corp [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	7,629
Accounts receivable	2,754
Property and equipment	8,813
Goodwill	31,705
Purchase price	25,500
Minority interest	(25,401)
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	18,383
Accounts receivable	44,289
Prepaid expenses and other current assets	11,292
Property and equipment	9,475
Goodwill	151,686
Purchase price	235,125
Clinical Consultants International L L C [Member]
Business Acquisition [Line Items]
Cash and cash equivalents	2,186
Goodwill	1,701,814
Purchase price	$ 1,704,000
Acenzia Inc [Member]
Business Acquisition [Line Items]
Cash and cash equivalents		3,738,171
Accounts receivable		808,165
Inventory		195,518
Prepaid expenses and other current assets		3,594
Property and equipment		5,687,988
Intangible assets		6,227,000
Goodwill		8,726,949
Accounts payable and accrued expenses		(1,845,114)
Due to related party		(185,614)
Note payable		(12,534,593)
Deferred tax liability		(1,536,000)
Lease obligation		(49,457)
Purchase price		9,236,607
Pro Dip [Member]
Business Acquisition [Line Items]
Cash and cash equivalents
Accounts receivable
Inventory		9,050
Prepaid expenses and other current assets
Property and equipment		16,355
Intangible assets		455,752
Goodwill
Accounts payable and accrued expenses
Due to related party
Note payable		(40,320)
Deferred tax liability
Lease obligation
Purchase price		$ 440,837

Summary of Purchase Price (Deta

Summary of Purchase Price (Details) - USD ($)	3 Months Ended		9 Months Ended	12 Months Ended
Summary of Purchase Price (Details) - USD ($)	May 31, 2022	May 31, 2021	May 31, 2022	Aug. 31, 2021	Aug. 31, 2020
Business Acquisition [Line Items]
Cash				$ 10,000
Issuance of common stock	$ 1,704,000	$ 430,837		430,837
Common stock to be issued			983,925
Purchase price, total			983,925
Canada Corp [Member]
Business Acquisition [Line Items]
Cash
Common stock to be issued			25,500
Purchase price, total			25,500
Poling Taddeo Hovius Physiotherapy Professional Corp [Member]
Business Acquisition [Line Items]
Cash
Common stock to be issued			235,125
Purchase price, total			235,125
Clinical Consultants International L L C [Member]
Business Acquisition [Line Items]
Cash
Common stock to be issued			1,704,000
Purchase price, total			$ 1,704,000
Acenzia Inc [Member]
Business Acquisition [Line Items]
Cash
Issuance of common stock
Common stock to be issued				9,236,607
Purchase price, total				9,236,607
Pro Dip [Member]
Business Acquisition [Line Items]
Cash				10,000
Issuance of common stock				430,837
Common stock to be issued
Purchase price, total				$ 440,837

Summary of Unaudited Pro Forma

Summary of Unaudited Pro Forma Results of Operations (Details) - Pro Forma [Member] - USD ($)	12 Months Ended
	Aug. 31, 2021	Aug. 31, 2020
Sales	$ 12,860,406	$ 14,047,859
Cost of goods sold	8,231,486	8,420,513
Gross profit	4,628,920	5,627,346
Operating expenses	10,285,972	14,091,463
Loss from operations	(5,657,052)	(8,464,117)
Net loss	$ (6,335,783)	$ (9,421,409)
Loss per share	$ (0.22)	$ (0.35)

Acquisitions (Details Narrative

Acquisitions (Details Narrative)

3 Months Ended

9 Months Ended

12 Months Ended

May 11, 2022 shares

Mar. 17, 2022 shares

Mar. 02, 2022 USD ($) $ / shares shares

Nov. 17, 2021 USD ($) $ / shares shares

Nov. 17, 2021 CAD ($) shares

Oct. 22, 2021 USD ($) $ / shares shares

Oct. 08, 2021 CAD ($) shares

Aug. 31, 2021 USD ($) $ / shares

Feb. 01, 2021

Dec. 11, 2020 USD ($) $ / shares shares

Dec. 17, 2019 shares

May 31, 2022 USD ($) $ / shares

Nov. 30, 2021 USD ($)

Aug. 31, 2021 USD ($) $ / shares

May 31, 2021 USD ($)

Nov. 30, 2020 USD ($)

May 31, 2022 USD ($) $ / shares

May 31, 2021 USD ($)

Aug. 31, 2021 USD ($) $ / shares shares

Aug. 31, 2020 USD ($)

Jul. 21, 2020 $ / shares

Business Acquisition [Line Items]

Purchase price of assets

$ 188,925

$ 876,000

Debt instrument convertible conversion price | $ / shares

$ 3.65

$ 15

Revenues

$ 13,851,883

$ 2,380,974

$ 19,883,033

$ 6,612,374

9,305,255

$ 7,860,567

Net income (loss)

(3,810,054)

(411,187)

(10,421,808)

$ (2,522,527)

(4,462,147)

(4,915,154)

Share price | $ / shares

$ 3.35

Business combination consideration transferred

$ 983,925

Stock Issued During Period, Value, New Issues

$ 7,235,580

$ 92,000

$ 7,327,580

$ 113,399

Reverse stock split

Purchase price per share | $ / shares

$ 2

Canada Corp [Member]

Business Acquisition [Line Items]

Revenues

$ 54,414

Net income (loss)

15,999

Number of restricted shares of common stock, shares | shares

17,000

Business combination consideration transferred

$ 25,500

Purchase price

$ 68,000

Purchase price per share | $ / shares

$ 4

Poling Taddeo Hovius Physiotherapy Professional Corp [Member]

Business Acquisition [Line Items]

Revenues

118,742

Net income (loss)

17,619

Number of restricted shares of common stock, shares | shares

156,750

Business combination consideration transferred

235,125

Purchase price

$ 627,000

Purchase price per share | $ / shares

$ 4

Clinical Consultants International L L C [Member]

Business Acquisition [Line Items]

Revenues

Net income (loss)

$ 717

Number of restricted shares of common stock, shares | shares

800,000

Business combination consideration transferred

$ 1,704,000

Canada Corp [Member]

Business Acquisition [Line Items]

Equity method investment ownership percentage

50.10%

Clinical Consultants International L L C [Member]

Business Acquisition [Line Items]

Equity method investment ownership percentage

100%

Ontario Inc [Member]

Business Acquisition [Line Items]

Common stock issued for intellectual property, shares | shares

240,000

Pro-Dip, LLC [Member]

Business Acquisition [Line Items]

Revenues

$ 1,172

Net income (loss)

$ 106,706

Asset Purchase Agreement [Member]

Business Acquisition [Line Items]

Purchase price of assets

$ 876,000

Common stock issued for intellectual property, shares | shares

240,000

Number of restricted shares of common stock, shares | shares

800,000

Share price | $ / shares

$ 3.65

Asset Purchase Agreement [Member] | Ontario Inc [Member]

Business Acquisition [Line Items]

Purchase price of assets

$ 876,000

Share Exchange Agreement [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

225,000

Share Exchange Agreement [Member] | Subsequent Event [Member]

Business Acquisition [Line Items]

Purchase price adjustment value

$ 14,162,795

Business combination consideration transferred

$ 398,050

$ 500,000

Shares issued, price per share | $ / shares

$ 3.35

Share Exchange Agreement [Member] | Subsequent Event [Member] | ACZ Shareholders [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

3,622,199

Share price | $ / shares

$ 3.91

Share Exchange Agreement [Member] | ACZ Shareholders [Member]

Business Acquisition [Line Items]

Revenues

$ 446,390

Net income (loss)

$ 549,666

Share Exchange Agreement [Member] | ACZ Shareholders [Member] | Subsequent Event [Member]

Business Acquisition [Line Items]

Business combination consideration transferred

$ 9,236,607

Share Exchange Agreement [Member] | Terragenx Inc [Member]

Business Acquisition [Line Items]

Business combination consideration transferred

$ 398,050

Ownership percentage

91%

Share Exchange Agreement [Member] | Terragenx [Member]

Business Acquisition [Line Items]

Revenues

$ 1,521,348

Net income (loss)

$ 115,427

Share price | $ / shares

$ 1.59

Business combination consideration transferred

$ 983,925

$ 500,000

Ownership percentage

91%

Shares issued, price per share | $ / shares

$ 3.35

Share exchange description

At the closing of the Exchange, (i) the Terra Shareholders transferred to NHL a total of 910 shares
of Terra common stock, representing 91% of Terra’s outstanding shares, and (ii) a total of 100 NHL Exchangeable Shares were issued
to the Terra Shareholders, which NHL Exchangeable Shares are exchangeable into a total of 118,821 restricted shares of the Company’s
common stock. As a result of the Exchange, NHL has 91% ownership of Terra and full control of the Terra business.

Common stock issued for cash, shares | shares

910

Business acquisition number of shares issued | shares

118,821

Share Exchange Agreement [Member] | Terragenx [Member] | Terry Mullins [Member]

Business Acquisition [Line Items]

Common stock issued for cash, shares | shares

500,000

Share Exchange Agreement [Member] | Terragenx [Member] | NHL [Member]

Business Acquisition [Line Items]

Common stock issued for cash, shares | shares

100

Mullins Asset Purchase Agreement [Member]

Business Acquisition [Line Items]

Shares issued, price per share | $ / shares

$ 3.35

Purchase of assets

$ 1,990,250

$ 2,500,000

Royalty paid description

the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales

Mullins Asset Purchase Agreement [Member] | Mr. Mullins [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

118,821

Share price | $ / shares

$ 1.59

Stock Issued During Period, Value, New Issues

$ 1,592,200

$ 2,000,000

Number of restricted shares of common stock

398,050

500,000

Asset acquisition consideration transferred

$ 188,925

Mullins Asset Purchase Agreement [Member] | Subsequent Event [Member]

Business Acquisition [Line Items]

Shares issued, price per share | $ / shares

$ 3.35

Purchase of assets

$ 1,990,250

$ 2,500,000

Royalty paid description

the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales

Mullins Asset Purchase Agreement [Member] | Subsequent Event [Member] | Mr. Mullins [Member]

Business Acquisition [Line Items]

Number of restricted shares of common stock, shares | shares

118,821

Stock Issued During Period, Value, New Issues

$ 1,592,200

$ 2,000,000

Number of restricted shares of common stock

$ 398,050

$ 500,000

Mullins Asset Purchase Agreement [Member] | Terragenx [Member] | Mr. Mullins [Member]

Business Acquisition [Line Items]

Number of shares issued, value

CAD$2,000,000
(approximately $1,592,200) is to be issued or allotted to Mr. Mullins only after patent-pending status, in the U.S. or internationally,
is designated for all Mullins IP Assets (the “Mullins IP Assets CAD$2m Shares”), as either restricted shares of Company
common stock or NHL Exchangeable Shares, as determined by Mr. Mullins. Once issued or allotted, the Mullins IP Assets CAD $2m Shares
will be held in escrow pending registration

Mullins Asset [Member] | Mr. Mullins [Member]

Business Acquisition [Line Items]

Asset acquisition consideration transferred

$ 755,701

Joint Venture Agreement [Member]

Business Acquisition [Line Items]

Common stock issued for cash, shares | shares

185,000

Proceeds from joint venture

$ 1,500,000

Reverse stock split

The net profits and net losses of the JV will be
split 50/50 between NHL and EK-Tech

Joint Venture Agreement [Member] | Subsequent Event [Member]

Business Acquisition [Line Items]

Common stock issued for cash, shares | shares

185,000

Proceeds from joint venture

$ 1,500,000

Reverse stock split

The net profits and net losses of the JV will be
split 50/50 between NHL and EK-Tech.

Schedule of Segment Reporting I

Schedule of Segment Reporting Information (Details) - USD ($)	3 Months Ended						9 Months Ended		12 Months Ended
	May 31, 2022	Feb. 28, 2022	Nov. 30, 2021	May 31, 2021	Feb. 28, 2021	Nov. 30, 2020	May 31, 2022	May 31, 2021	Aug. 31, 2021	Aug. 31, 2020	Aug. 31, 2019
Segment Reporting Information [Line Items]
Sales	$ 13,851,883			$ 2,380,974			$ 19,883,033	$ 6,612,374	$ 9,305,255	$ 7,860,567
Gross profit	2,408,882			1,280,458			4,891,702	2,843,354	3,822,998	3,058,372
Income (loss) from operations	(1,202,746)			(401,972)			(4,687,081)	(2,485,640)	(4,373,519)	(4,262,598)
Depreciation and amortization	881,597			381,502			2,349,434	1,118,925	1,724,122	1,445,076
Capital expenditures				200,751			190,973	201,369	255,949	12,110
Interest expenses	513,398			21,701			1,808,310	68,590	165,003	156,662
Net income (loss)	(3,810,054)			(411,187)			(10,421,808)	(2,522,527)	(4,462,147)	(4,915,154)
Total assets	71,792,814						71,792,814		61,958,281	35,390,618
Accounts receivable	5,166,239						5,166,239		1,468,429	1,732,432
Intangible assets	32,192,858						32,192,858		32,029,499	26,623,448
Goodwill	11,366,618						11,366,618		9,488,848	636,942
Net income (loss)	(3,744,025)	$ (4,868,204)	$ (1,816,395)	(415,271)	$ (1,340,591)	$ (773,103)	(10,428,624)	(2,528,965)	(4,470,935)	(4,924,209)
Previously Reported [Member]
Segment Reporting Information [Line Items]
Total assets									61,958,281
Accounts receivable									1,468,429
Intangible assets									32,436,468
Goodwill									9,081,879	636,942	$ 623,081
Healthcare Services [Member]
Segment Reporting Information [Line Items]
Sales	2,199,889			2,380,974			6,253,089	6,612,374	8,857,693	7,860,567
Gross profit	939,542			1,280,458			2,499,608	2,843,354	3,694,512	3,058,372
Income (loss) from operations	(239,981)			255,129			(616,303)	(99,454)	(516,437)	442,656
Depreciation and amortization	249,831			13,902			393,942	57,840	91,978	75,726
Capital expenditures				200,751			175,418	201,369	216,284	12,110
Interest expenses	14,532			21,701			54,686	68,590	89,154	156,662
Net income (loss)									(552,893)	(232,991)
Total assets	6,491,538						6,491,538		7,318,888	7,607,820
Accounts receivable	815,833						815,833		953,919	1,732,432
Intangible assets
Goodwill	741,209						741,209		557,357	636,942
Net income (loss)	(252,122)			235,867			(663,646)	(160,492)
Product Manufacturing and Development [Member]
Segment Reporting Information [Line Items]
Sales									447,562
Gross profit									128,486
Income (loss) from operations									(580,523)
Depreciation and amortization									203,459
Capital expenditures									39,665
Interest expenses									75,849
Net income (loss)									(656,372)
Total assets									21,427,285
Accounts receivable									514,510
Intangible assets									6,365,705
Goodwill									8,524,522
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Sales
Gross profit
Income (loss) from operations	(1,299,113)			(657,101)			(3,561,436)	(2,386,186)	(3,276,559)	(4,705,254)
Depreciation and amortization	367,600			367,600			1,102,800	1,061,085	1,428,685	1,369,350
Capital expenditures
Interest expenses	404,101						686,413
Net income (loss)									(3,252,882)	(4,682,163)
Total assets	40,470,565						40,470,565		33,212,108	27,782,798
Accounts receivable	2,585,932						2,585,932
Intangible assets	24,967,963						24,967,963		26,070,763	26,623,448
Goodwill	1,701,814						1,701,814
Net income (loss)	(3,470,750)			(651,138)			(7,123,887)	(2,368,473)
Product Sales [Member]
Segment Reporting Information [Line Items]
Sales	11,651,994						13,629,944
Gross profit	1,469,340						2,392,094
Income (loss) from operations	336,348						(509,342)
Depreciation and amortization	266,166						852,692
Capital expenditures							15,555
Interest expenses	94,765						1,067,211
Total assets	24,830,711						24,830,711		21,427,285
Accounts receivable	1,764,474						1,764,474		514,510
Intangible assets	7,224,895						7,224,895		5,958,736
Goodwill	8,923,595						8,923,595		$ 8,931,491
Net income (loss)	$ (21,153)						$ (2,641,091)

Segment Reporting (Details Narr

Segment Reporting (Details Narrative)	12 Months Ended
Segment Reporting (Details Narrative)	Aug. 31, 2021 USD ($) Integer	May 31, 2022 USD ($)	Aug. 31, 2020 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of reportable segments \| Integer	2
Property and equipment	$ 6,070,291	$ 5,931,683	$ 353,660
CANADA
Revenues from External Customers and Long-Lived Assets [Line Items]
Property and equipment	$ 16,355

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

3 Months Ended

9 Months Ended

12 Months Ended

Jul. 12, 2022 USD ($) shares

Jul. 05, 2022 shares

Jun. 30, 2022 USD ($)

Jun. 29, 2022 shares

Jun. 14, 2022 USD ($)

Jun. 01, 2022 USD ($)

May 11, 2022 shares

Dec. 14, 2021 USD ($) $ / shares shares

Nov. 17, 2021 USD ($) $ / shares shares

Nov. 17, 2021 CAD ($) shares

Oct. 08, 2021 CAD ($) shares

Oct. 02, 2021 $ / shares shares

May 24, 2021 USD ($) shares

Feb. 01, 2021

Jul. 21, 2020 $ / shares shares

May 31, 2022 USD ($) $ / shares shares

May 31, 2021 USD ($)

Nov. 30, 2020 USD ($)

May 31, 2022 USD ($) $ / shares shares

May 31, 2021 USD ($) shares

Aug. 31, 2021 USD ($) $ / shares

Aug. 31, 2020 USD ($)

Dec. 11, 2020 $ / shares

Subsequent Event [Line Items]

Exercise price | $ / shares

$ 2.16

$ 2.29

Reverse stock split, description

Business combination consideration transferred

$ 983,925

Common stock issued for cash, net of offering costs

$ 7,235,580

$ 92,000

$ 7,327,580

$ 113,399

Debt Instrument, Maturity Date

May 17, 2022

Sep. 01, 2022

Debt face amount

$ 1,875,000

16,666,666

Payments of related party debt

21,932

$ 177,534

$ 246,327

$ 198,778

Original issue discount

$ 2,133,890

$ 3,654,752

Conversion price | $ / shares

$ 15

$ 3.65

Warrants issued | shares

223,880

5,833,334

Debt conversion, shares issued | shares

15,091

8,270,812

4,308,591

Proceeds from issuance of convertible notes

$ 15,270,000

Convertible notes payable

$ 1,579,176

$ 11,409,200

11,409,200

Convertible note payable

$ 1,875,000

Terragenx Inc [Member]

Subsequent Event [Line Items]

Ownership Percentage

91%

Debt face amount

$ 937,500

Convertible notes payable

$ 1,875,000

Joint Venture Agreement [Member]

Subsequent Event [Line Items]

Proceeds from Joint Venture

$ 1,500,000

Number of shares issued | shares

185,000

Reverse stock split, description

The net profits and net losses of the JV will be
split 50/50 between NHL and EK-Tech

Share Exchange Agreement [Member]

Subsequent Event [Line Items]

Number of restricted shares of common stock, shares | shares

225,000

Mullins Asset Purchase Agreement [Member]

Subsequent Event [Line Items]

Shares issued price per share | $ / shares

$ 3.35

Purchase of Assets

$ 1,990,250

$ 2,500,000

Royalty Paid Description

the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales

Mullins Asset Purchase Agreement [Member] | Mr. Mullins [Member]

Subsequent Event [Line Items]

Common stock issued for cash, net of offering costs

$ 1,592,200

$ 2,000,000

Number of restricted shares of common stock

$ 398,050

$ 500,000

Number of restricted shares of common stock, shares | shares

118,821

Share Purchase Agreement [Member]

Subsequent Event [Line Items]

Number of restricted shares of common stock

$ 430,837

Number of restricted shares of common stock, shares | shares

189,796

Subsequent Event [Member] | Promissory Note Amortization Payment [Member]

Subsequent Event [Line Items]

Principal and interest owed

$ 1,391,589

Subsequent event description

Payment pursuant to
the terms and conditions of the $16.66m+ convertible notes

Subsequent Event [Member] | Restricted Stock Issuance For Independent Contractor Agreement [Member]

Subsequent Event [Line Items]

Restricted common stock shares | shares

50,000

Subsequent Event [Member] | Senior Secured Convertible Notes [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

12,572

Debt face amount

$ 143

Convertible note payable

$ 25,000

Subsequent Event [Member] | Acenzia Promissory Note [Member]

Subsequent Event [Line Items]

Principal and interest owed

$ 5,300,000

Subsequent Event [Member] | Sarfaraz Ali [Member]

Subsequent Event [Line Items]

Directors description

(i) Sarfaraz Ali was appointed as a member of the Board of Directors; (ii) the size of the Board of Directors was reduced from
seven to five members. The Board of Directors has undertaken a review of Mr. Ali’s independence and determined that Mr. Ali does
not have a material relationship with the Company that could compromise his ability to exercise independent judgment in carrying out
his responsibilities and that Mr. Ali is “independent” as that term is defined under the listing standards of The Nasdaq
Stock Market LLC

Changes in fair value market

$ 75,000

Subsequent Event [Member] | Terragenx Inc [Member] | Promissory Notes Payment [Member]

Subsequent Event [Line Items]

Convertible notes payable

$ 1,875,000

Principal and interest owed

948,874

Subsequent Event [Member] | Terragenx Inc [Member] | Promissory Notes Payment And Extension [Member]

Subsequent Event [Line Items]

Convertible notes payable

1,875,000

Principal and interest owed

937,500

Convertible note payable

$ 192,188

Maturity date

Nov. 29, 2022

Subsequent Event [Member] | Joint Venture Agreement [Member]

Subsequent Event [Line Items]

Proceeds from Joint Venture

$ 1,500,000

Number of shares issued | shares

185,000

Reverse stock split, description

The net profits and net losses of the JV will be
split 50/50 between NHL and EK-Tech.

Subsequent Event [Member] | Share Exchange Agreement [Member]

Subsequent Event [Line Items]

Business combination consideration transferred

$ 398,050

$ 500,000

Shares issued price per share | $ / shares

$ 3.35

Subsequent Event [Member] | Share Exchange Agreement [Member] | Terragenx Inc [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

100

Ownership Percentage

91%

Business acquisition number of shares issued | shares

118,821

Subsequent Event [Member] | Share Exchange Agreement [Member] | Novo Healthnet Limited [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

910

Ownership Percentage

91%

Share exchange description

Subsequent Event [Member] | Mullins Asset Purchase Agreement [Member]

Subsequent Event [Line Items]

Shares issued price per share | $ / shares

$ 3.35

Purchase of Assets

$ 1,990,250

$ 2,500,000

Royalty Paid Description

the Company will pay a royalty equal to 10% of net revenue (net profit) of all iodine related sales

Subsequent Event [Member] | Mullins Asset Purchase Agreement [Member] | Mr. Mullins [Member]

Subsequent Event [Line Items]

Common stock issued for cash, net of offering costs

$ 1,592,200

$ 2,000,000

Number of restricted shares of common stock

$ 398,050

$ 500,000

Number of restricted shares of common stock, shares | shares

118,821

Subsequent Event [Member] | Mullins Asset Purchase Agreement [Member] | Terragenx Inc [Member] | Mr. Mullins [Member]

Subsequent Event [Line Items]

Purchase Commitment

Subsequent Event [Member] | Jefferson Street Capital Stock Purchase Agreement [Member]

Subsequent Event [Line Items]

Exercise price | $ / shares

$ 3.35

Number of shares issued | shares

1,000,000

Common stock issued for cash, net of offering costs

$ 750,000

Debt instrument, issuance date

Nov. 17, 2021

Debt Instrument, Maturity Date

May 17, 2022

Debt face amount

$ 937,500

Payments of related party debt

937,500

Purchase price

750,000

Original issue discount

$ 187,500

Debt Instrument, Interest Rate

Conversion price | $ / shares

$ 3.35

Repayments of debt

$ 750,000

Warrants issued | shares

111,940

Subsequent Event [Member] | Platinum Point Capital Stock Purchase Agreement [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

1,000,000

Common stock issued for cash, net of offering costs

$ 750,000

Debt instrument, issuance date

Nov. 17, 2021

Debt Instrument, Maturity Date

May 17, 2022

Debt face amount

$ 937,500

Payments of related party debt

937,500

Purchase price

750,000

Original issue discount

$ 187,500

Debt Instrument, Interest Rate

Conversion price | $ / shares

$ 3.35

Repayments of debt

$ 750,000

Subsequent Event [Member] | Platinum Point Capital Common Stock Purchase Warrant [Member]

Subsequent Event [Line Items]

Number of shares issued | shares

111,940

Conversion price | $ / shares

$ 3.35

Subsequent Event [Member] | Share Purchase Agreement [Member] | Purchaser [Member]

Subsequent Event [Line Items]

Warrants issued | shares

5,833,334

Warrant exercise price | $ / shares

$ 2

Subsequent Event [Member] | Share Purchase Agreement [Member] | Purchaser [Member] | Senior Secured Convertible Notes [Member]

Subsequent Event [Line Items]

Debt Instrument, Maturity Date

Jun. 14, 2023

Debt face amount

$ 16,666,666

Original issue discount

$ 1,388,888

Debt Instrument, Interest Rate

Conversion price | $ / shares

$ 2

Debt conversion, shares issued | shares

68,557,248

Stock issued upon warrant exercise, shares | shares

5,833,334

Debt issuance discount, percentage

10%

Proceeds from issuance of convertible notes

$ 15,000,000

Equity blocker

9.99%

Debt default, description

If an event of default occurs,
the holder may convert all, or any part, of the principal amount of a Note and all accrued and unpaid interest and late charge at an
alternate conversion price, as described in the Notes. Subject to certain conditions, the Company has the right to redeem all, but not
less than all, of the remaining principal amount of the Notes and all accrued and unpaid interest and late charges in cash at a price
equal to 135% of the amount being redeemed.

Subsequent Event [Member] | 2021 Plan Option Grant [Member]

Subsequent Event [Line Items]

Options granted | shares

48,000

Exercise price | $ / shares

$ 1.87

Options expiration, date

Oct. 01, 2026

Subsequent Event [Member] | Twenty Twenty One [Member] | Michael Gaynor [Member]

Subsequent Event [Line Items]

Common stock pursuant shares | shares

50,000

Service period

5 years

Subsequent Event [Member] | Twenty Twenty One [Member] | Pierre Dalcourt [Member] | Board of Directors Chairman [Member]

Subsequent Event [Line Items]

Common stock pursuant shares | shares

250,000

Service period

5 years

Schedule of Warrant Activity (D

Schedule of Warrant Activity (Details)	9 Months Ended
Schedule of Warrant Activity (Details)	May 31, 2022 USD ($) $ / shares shares
Convertible Notes Payable
Warrants outstanding, beginning balance	2,388,050
Weighted average exercise price, outstanding, beginning balance \| $ / shares	$ 3.35
Weighted average remaining contractual life, outstanding, beginning balance \| $ / shares	$ 5.12
Aggregate intrinsic value, outstanding, beginning balance \| $
Warrants outstanding, granted	6,057,214
Weighted average exercise price, granted \| $ / shares	$ 2.05
Warrants outstanding, forfeited
Warrants outstanding, exercised
Warrants outstanding, ending balance	8,445,264
Weighted average exercise price, outstanding, ending balance \| $ / shares	$ 2.42
Weighted average remaining contractual life, outstanding, ending balance	3 years 9 months
Aggregate intrinsic value, outstanding, ending balance \| $	$ 291,667
Warrants outstanding, exercisable	8,445,264
Weighted average exercise price, exercisable \| $ / shares	$ 2.42
Weighted average remaining contractual life, exercisable	3 years 9 months
Aggregate intrinsic value, exercisable \| $	$ 291,667

Schedule of Warrants Outstandin

Schedule of Warrants Outstanding (Details) - Exercise Price Range [Member]	May 31, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options/Warrants, Outstanding	5,833,334
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 2
Number of Options/Warrants, Outstanding	2,611,930
Number of Options/Warrants, Outstanding, Exercise Price \| $ / shares	$ 3.35
Number of Options/Warrants, Exercisable	8,445,264

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative)				3 Months Ended		9 Months Ended		12 Months Ended
Convertible Notes Payable (Details Narrative)	Dec. 14, 2021 USD ($) $ / shares	Nov. 17, 2021 USD ($) $ / shares shares	Jul. 21, 2020 shares	May 31, 2022 USD ($) $ / shares shares	May 31, 2021 USD ($)	May 31, 2022 USD ($) $ / shares shares	May 31, 2021 USD ($) shares	Aug. 31, 2021	Aug. 31, 2020
Convertible Notes Payable		$ 1,579,176		$ 11,409,200		$ 11,409,200
Convertible notes payable face amount		$ 1,875,000		$ 16,666,666		$ 16,666,666
Debt rate	5%	1%							10%
Debt Instrument, Maturity Date		May 17, 2022						Sep. 01, 2022
Share Price \| $ / shares		$ 3.35
Convertible notes payable, note holders issued warrants to purchase total, shares \| shares		223,880		5,833,334		5,833,334
Common stock per shares \| $ / shares				$ 2		$ 2
Redemption of warrants description		The warrants expire on November 17, 2024. The Company first determined the value of the $1.875m convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $351,240 and was determined using the Black-Scholes option pricing model with the following assumption				The warrants expire on December 14, 2025. The Company first determined the value of the $16.66m+ convertible notes and the fair value of the detachable warrants issued in connection with this transaction. The estimated value of the warrants of $7,680,156 was determined using the Black-Scholes option pricing model with the following assumptions
Number Of Estimated Value Warrants Or Rights		$ 351,240		$ 7,680,156		$ 7,680,156
Warrants and rights outstanding, term				4 years		4 years
Discount on convertable note and additional paid in capital		295,824		$ 5,257,466		$ 5,257,466
Original issue discount		375,000		1,666,666		1,666,666
Debt Instrument, Fee Amount		90,000		1,140,000		1,140,000
Amortization of debt discount (premium)				2,133,890		3,654,752
Debt instrument debt discount				2,893,927		2,893,927
Debt instrument unamortization debt discount				5,170,205		$ 5,170,205
Debt conversion, converted instrument, shares issued \| shares			15,091			8,270,812	4,308,591
Convertible Debt [Member]
Debt instrument debt discount				760,824		$ 760,824
Debt instrument unamortization debt discount				0		0
Debt instrument aggregate principal amount				1,244,444		1,244,444
Accrued interest				$ 3,405		3,405
Debt conversion, converted instrument, shares issued \| shares				623,929
Convertible Notes [Member]
Amortization of debt discount (premium)		$ 760,824				8,064,132
Warrant [Member]
Convertible Notes Payable				$ 5,257,466		$ 5,257,466
Measurement Input, Price Volatility [Member]
Measurement input percentage		300		275		275
Measurement Input, Expected Dividend Rate [Member]
Measurement input percentage		0		0		0
Measurement Input, Risk Free Interest Rate [Member]
Measurement input percentage		0.85
Measurement input percentage						1.23%
Measurement Input, Expected Term [Member]
Warrants and rights outstanding, term		3 years
Novo Integrated [Member]
Convertible Notes Payable	$ 16,666,666
Convertible notes payable face amount	$ 8,333,333
Debt Instrument, Maturity Date	Jun. 14, 2023
Share Price \| $ / shares	$ 2
Terragenx Inc [Member]
Convertible Notes Payable		$ 1,875,000
Convertible notes payable face amount		$ 937,500
Ownership Percentage		91%